[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f3tWGPEEprTvgoKq6yYsX17-_BipJ4NQ3S-h2DDqVu8U":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":88,"rows":95},"Federal University of São Paulo",[4],434,false,24,49,101782,18,300,[14,17,20,23,25,28,31,34],{"name":15,"count":16},"Obesity",13,{"name":18,"count":19},"Fibromyalgia",11,{"name":21,"count":22},"Rheumatoid Arthritis",10,{"name":24,"count":22},"Pain",{"name":26,"count":27},"Knee Osteoarthritis",8,{"name":29,"count":30},"Inflammation",7,{"name":32,"count":33},"Physical Activity",6,{"name":35,"count":36},"Chronic Pain",5,[38,43,48,53,58,63,68,73,78,83],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT06761313","Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma","2024-12-10","Triple combination formula",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT04453436","HIV Drug Resistance Among Individuals Failing Tenofovir\u002FLamivudine and Dolutegravir First Line Regimen in Brazil","2024-12-31","Tenofovir Disoproxil",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT06542393","PBM as Strategy to CABG Anemic Patients Bypass Graft (CABG)","2025-06-01","Erythropoietin",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT04045379","LASER and Radiofrequency and Genitourinary Syndrome of Menopause","2025-08","Estriol",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT04081805","LASER and Radiofrequency for Treatment of Vaginal Vulvar Atrophy (VVA) in Women Treated for Breast Cancer (EPMLARF-arm2)","2025-09","Promestriene",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT06799650","Clinical Trial of Gammora® Plus Antiretroviral Treatment for HIV","2025-11-01","Gammora®",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT06858228","Comparison of Denervation Techniques for the Treatment of Knee Osteoarthritis: Continuous Ablative Radiofrequency Vs. Chemical Denervation with Absolute Alcohol","2026-09","Chemical Denervation with Absolute Alcohol",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT06805656","Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Antiretrovirals","2027-01-01","Maraviroc",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT07242729","Bone Marrow Aspirate Versus Platelet-Rich Fibrin for the Treatment of Chronic Plantar Fasciitis","2027-02-01","Bone Marrow Aspirate",{"nctId":84,"briefTitle":85,"date":86,"intervention":87},"NCT06905860","Intra-articular Infiltration of Platelet-Rich Fibrin vs Corticosteroid in Mild to Moderate Knee Osteoarthritis","2027-06-01","Platelet-rich fibrin",[89,90,91,92,93,94],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[96,132,157,175,193,234,265,286,315,354,376,398,420,442,460,482,505,527,550,585,615,653,695,719,745,767,808,826,844,862,880,898,916,934,952,970,988,1006,1024,1051,1069,1094,1122,1140,1158,1176,1205,1223,1247,1273,1291,1317,1342,1366,1393,1411,1429,1456,1474,1497,1521,1548,1566,1594,1612,1635,1659,1677,1695,1720,1738,1756,1779,1804,1822,1867,1889,1912,1937,1962,1980,2006,2034,2052,2079,2097,2115,2138,2165,2183,2207,2225,2247,2272,2296,2318,2341,2366,2384,2409,2434,2460,2486,2504,2522,2547,2571,2603,2626,2644,2671,2692,2715,2737,2760,2782,2808,2829,2853,2871,2889,2917,2944,2962,2987,3010,3034,3052,3076,3100,3124,3169,3199,3241,3287,3323,3358,3393,3428,3453,3476,3501,3530,3553,3577,3600,3618,3640,3663,3685,3708,3730,3752,3777,3806,3824,3842,3860,3878,3900,3918,3936,3954,3972,3990,4008,4026,4053,4071,4093,4116,4138,4164,4182,4204,4222,4246,4264,4282,4307,4332,4353],{"intervention":97,"totalTrials":98,"cells":99},"Platelet-Rich Fibrin",2,{"EARLY_PHASE1":100,"PHASE1":103,"PHASE2":105,"PHASE3":107,"PHASE4":109,"NA":121},{"trials":101,"activeCount":102},[],0,{"trials":104,"activeCount":102},[],{"trials":106,"activeCount":102},[],{"trials":108,"activeCount":102},[],{"trials":110,"activeCount":120,"soonestReadout":86},[111],{"nctId":84,"briefTitle":85,"status":112,"phases":113,"primaryCompletion":86,"completion":114,"start":51,"enrollment":115,"conditions":116,"interventions":118},"NOT_YET_RECRUITING",[93],"2027-09-01",90,[117],"Gonarthrosis; Primary",[87,119],"Corticosteroid",1,{"trials":122,"activeCount":120,"soonestReadout":81},[123],{"nctId":79,"briefTitle":80,"status":124,"phases":125,"primaryCompletion":81,"completion":126,"start":127,"enrollment":128,"conditions":129,"interventions":131},"RECRUITING",[94],"2028-02-01","2025-02-01",72,[130],"Plantar Fasciitis",[82,97],{"intervention":42,"totalTrials":120,"cells":133},{"EARLY_PHASE1":134,"PHASE1":136,"PHASE2":138,"PHASE3":140,"PHASE4":142,"NA":155},{"trials":135,"activeCount":102},[],{"trials":137,"activeCount":102},[],{"trials":139,"activeCount":102},[],{"trials":141,"activeCount":102},[],{"trials":143,"activeCount":120,"soonestReadout":41},[144],{"nctId":39,"briefTitle":40,"status":145,"phases":146,"primaryCompletion":41,"completion":147,"start":148,"enrollment":149,"conditions":150,"interventions":153},"ACTIVE_NOT_RECRUITING",[93],"2025-02-26","2021-03-01",40,[151,152],"Glaucoma","Quality of Life (QOL)",[42,154],"Bimatoprost .03% sterile ophthalmic solution",{"trials":156,"activeCount":102},[],{"intervention":154,"totalTrials":120,"cells":158},{"EARLY_PHASE1":159,"PHASE1":161,"PHASE2":163,"PHASE3":165,"PHASE4":167,"NA":173},{"trials":160,"activeCount":102},[],{"trials":162,"activeCount":102},[],{"trials":164,"activeCount":102},[],{"trials":166,"activeCount":102},[],{"trials":168,"activeCount":120,"soonestReadout":41},[169],{"nctId":39,"briefTitle":40,"status":145,"phases":170,"primaryCompletion":41,"completion":147,"start":148,"enrollment":149,"conditions":171,"interventions":172},[93],[151,152],[42,154],{"trials":174,"activeCount":102},[],{"intervention":119,"totalTrials":120,"cells":176},{"EARLY_PHASE1":177,"PHASE1":179,"PHASE2":181,"PHASE3":183,"PHASE4":185,"NA":191},{"trials":178,"activeCount":102},[],{"trials":180,"activeCount":102},[],{"trials":182,"activeCount":102},[],{"trials":184,"activeCount":102},[],{"trials":186,"activeCount":120,"soonestReadout":86},[187],{"nctId":84,"briefTitle":85,"status":112,"phases":188,"primaryCompletion":86,"completion":114,"start":51,"enrollment":115,"conditions":189,"interventions":190},[93],[117],[87,119],{"trials":192,"activeCount":102},[],{"intervention":194,"totalTrials":98,"cells":195},"Midazolam",{"EARLY_PHASE1":196,"PHASE1":198,"PHASE2":200,"PHASE3":202,"PHASE4":216,"NA":232},{"trials":197,"activeCount":102},[],{"trials":199,"activeCount":102},[],{"trials":201,"activeCount":102},[],{"trials":203,"activeCount":120,"soonestReadout":208},[204],{"nctId":205,"briefTitle":206,"status":112,"phases":207,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":211,"interventions":214},"NCT06957704","Evaluation of the Efficacy and Safety of Subcutaneous Ketamine in the Treatment of Depressive Episode With Suicidal Ideation and\u002For Behavior in Adolescents",[92],"2028-04","2025-05",60,[212,213],"Depressive Disorder","Suicidal Ideas",[215,194],"ketamine",{"trials":217,"activeCount":102},[218],{"nctId":219,"briefTitle":220,"status":221,"phases":222,"primaryCompletion":223,"completion":224,"start":225,"enrollment":226,"conditions":227,"interventions":229},"NCT00906139","Propofol and Fentanyl Versus Midazolam and Fentanyl for Endoscopy Sedation in Cirrhotic Patients","UNKNOWN",[93],"2009-02","2009-11","2008-03",210,[228],"Cirrhosis",[230,194,231],"Propofol","Fentanyl",{"trials":233,"activeCount":102},[],{"intervention":235,"totalTrials":98,"cells":236},"Ketamine",{"EARLY_PHASE1":237,"PHASE1":239,"PHASE2":241,"PHASE3":243,"PHASE4":261,"NA":263},{"trials":238,"activeCount":102},[],{"trials":240,"activeCount":102},[],{"trials":242,"activeCount":102},[],{"trials":244,"activeCount":120,"soonestReadout":208},[245,257],{"nctId":246,"briefTitle":247,"status":248,"phases":249,"primaryCompletion":250,"completion":250,"start":251,"enrollment":210,"conditions":252,"interventions":255},"NCT01301079","Evaluation of the Effect of Ketamine on Remifentanil-induced Hyperalgesia","COMPLETED",[92],"2012-09","2010-09",[24,253,254],"Hyperalgesia","Inflammatory Response",[235,256],"Saline",{"nctId":205,"briefTitle":206,"status":112,"phases":258,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":259,"interventions":260},[92],[212,213],[215,194],{"trials":262,"activeCount":102},[],{"trials":264,"activeCount":102},[],{"intervention":67,"totalTrials":120,"cells":266},{"EARLY_PHASE1":267,"PHASE1":269,"PHASE2":271,"PHASE3":280,"PHASE4":282,"NA":284},{"trials":268,"activeCount":102},[],{"trials":270,"activeCount":102},[],{"trials":272,"activeCount":120,"soonestReadout":66},[273],{"nctId":64,"briefTitle":65,"status":145,"phases":274,"primaryCompletion":66,"completion":275,"start":276,"enrollment":149,"conditions":277,"interventions":279},[91],"2026-11-01","2025-01-01",[278],"HIV Seropositivity",[67],{"trials":281,"activeCount":102},[],{"trials":283,"activeCount":102},[],{"trials":285,"activeCount":102},[],{"intervention":52,"totalTrials":120,"cells":287},{"EARLY_PHASE1":288,"PHASE1":290,"PHASE2":292,"PHASE3":309,"PHASE4":311,"NA":313},{"trials":289,"activeCount":102},[],{"trials":291,"activeCount":102},[],{"trials":293,"activeCount":120,"soonestReadout":51},[294],{"nctId":49,"briefTitle":50,"status":124,"phases":295,"primaryCompletion":51,"completion":296,"start":297,"enrollment":298,"conditions":299,"interventions":308},[91],"2026-06-01","2024-06-01",120,[300,301,302,303,304,305,306,307],"Anemia","Coronary Disease","Coronary Artery Disease","Coronary Stenosis","Coronary Occlusion","Systemic Inflammatory Response","Bleeding","Epigenetic Disorder",[52],{"trials":310,"activeCount":102},[],{"trials":312,"activeCount":102},[],{"trials":314,"activeCount":102},[],{"intervention":77,"totalTrials":98,"cells":316},{"EARLY_PHASE1":317,"PHASE1":319,"PHASE2":321,"PHASE3":336,"PHASE4":338,"NA":340},{"trials":318,"activeCount":102},[],{"trials":320,"activeCount":102},[],{"trials":322,"activeCount":120,"soonestReadout":76},[323],{"nctId":74,"briefTitle":75,"status":112,"phases":324,"primaryCompletion":76,"completion":325,"start":326,"enrollment":327,"conditions":328,"interventions":331},[91],"2027-12-31","2026-07-01",70,[329,330],"Hiv","HIV I Infection",[77,332,333,334,335],"Dolutegravir","Dendritic Cell Vaccine","Auranofin","Sirtuin Histone deacetylase inhibitor",{"trials":337,"activeCount":102},[],{"trials":339,"activeCount":102},[],{"trials":341,"activeCount":102},[342],{"nctId":343,"briefTitle":344,"status":248,"phases":345,"primaryCompletion":346,"completion":347,"start":348,"enrollment":349,"conditions":350,"interventions":353},"NCT02961829","Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure",[94],"2019-03","2020-03","2015-07",30,[351,352],"Chronic Infection","HIV",[77,332,333,334,335],{"intervention":332,"totalTrials":98,"cells":355},{"EARLY_PHASE1":356,"PHASE1":358,"PHASE2":360,"PHASE3":366,"PHASE4":368,"NA":370},{"trials":357,"activeCount":102},[],{"trials":359,"activeCount":102},[],{"trials":361,"activeCount":120,"soonestReadout":76},[362],{"nctId":74,"briefTitle":75,"status":112,"phases":363,"primaryCompletion":76,"completion":325,"start":326,"enrollment":327,"conditions":364,"interventions":365},[91],[329,330],[77,332,333,334,335],{"trials":367,"activeCount":102},[],{"trials":369,"activeCount":102},[],{"trials":371,"activeCount":102},[372],{"nctId":343,"briefTitle":344,"status":248,"phases":373,"primaryCompletion":346,"completion":347,"start":348,"enrollment":349,"conditions":374,"interventions":375},[94],[351,352],[77,332,333,334,335],{"intervention":333,"totalTrials":98,"cells":377},{"EARLY_PHASE1":378,"PHASE1":380,"PHASE2":382,"PHASE3":388,"PHASE4":390,"NA":392},{"trials":379,"activeCount":102},[],{"trials":381,"activeCount":102},[],{"trials":383,"activeCount":120,"soonestReadout":76},[384],{"nctId":74,"briefTitle":75,"status":112,"phases":385,"primaryCompletion":76,"completion":325,"start":326,"enrollment":327,"conditions":386,"interventions":387},[91],[329,330],[77,332,333,334,335],{"trials":389,"activeCount":102},[],{"trials":391,"activeCount":102},[],{"trials":393,"activeCount":102},[394],{"nctId":343,"briefTitle":344,"status":248,"phases":395,"primaryCompletion":346,"completion":347,"start":348,"enrollment":349,"conditions":396,"interventions":397},[94],[351,352],[77,332,333,334,335],{"intervention":334,"totalTrials":98,"cells":399},{"EARLY_PHASE1":400,"PHASE1":402,"PHASE2":404,"PHASE3":410,"PHASE4":412,"NA":414},{"trials":401,"activeCount":102},[],{"trials":403,"activeCount":102},[],{"trials":405,"activeCount":120,"soonestReadout":76},[406],{"nctId":74,"briefTitle":75,"status":112,"phases":407,"primaryCompletion":76,"completion":325,"start":326,"enrollment":327,"conditions":408,"interventions":409},[91],[329,330],[77,332,333,334,335],{"trials":411,"activeCount":102},[],{"trials":413,"activeCount":102},[],{"trials":415,"activeCount":102},[416],{"nctId":343,"briefTitle":344,"status":248,"phases":417,"primaryCompletion":346,"completion":347,"start":348,"enrollment":349,"conditions":418,"interventions":419},[94],[351,352],[77,332,333,334,335],{"intervention":335,"totalTrials":98,"cells":421},{"EARLY_PHASE1":422,"PHASE1":424,"PHASE2":426,"PHASE3":432,"PHASE4":434,"NA":436},{"trials":423,"activeCount":102},[],{"trials":425,"activeCount":102},[],{"trials":427,"activeCount":120,"soonestReadout":76},[428],{"nctId":74,"briefTitle":75,"status":112,"phases":429,"primaryCompletion":76,"completion":325,"start":326,"enrollment":327,"conditions":430,"interventions":431},[91],[329,330],[77,332,333,334,335],{"trials":433,"activeCount":102},[],{"trials":435,"activeCount":102},[],{"trials":437,"activeCount":102},[438],{"nctId":343,"briefTitle":344,"status":248,"phases":439,"primaryCompletion":346,"completion":347,"start":348,"enrollment":349,"conditions":440,"interventions":441},[94],[351,352],[77,332,333,334,335],{"intervention":82,"totalTrials":120,"cells":443},{"EARLY_PHASE1":444,"PHASE1":446,"PHASE2":448,"PHASE3":450,"PHASE4":452,"NA":454},{"trials":445,"activeCount":102},[],{"trials":447,"activeCount":102},[],{"trials":449,"activeCount":102},[],{"trials":451,"activeCount":102},[],{"trials":453,"activeCount":102},[],{"trials":455,"activeCount":120,"soonestReadout":81},[456],{"nctId":79,"briefTitle":80,"status":124,"phases":457,"primaryCompletion":81,"completion":126,"start":127,"enrollment":128,"conditions":458,"interventions":459},[94],[130],[82,97],{"intervention":72,"totalTrials":120,"cells":461},{"EARLY_PHASE1":462,"PHASE1":464,"PHASE2":466,"PHASE3":468,"PHASE4":470,"NA":472},{"trials":463,"activeCount":102},[],{"trials":465,"activeCount":102},[],{"trials":467,"activeCount":102},[],{"trials":469,"activeCount":102},[],{"trials":471,"activeCount":102},[],{"trials":473,"activeCount":120,"soonestReadout":71},[474],{"nctId":69,"briefTitle":70,"status":112,"phases":475,"primaryCompletion":71,"completion":476,"start":477,"enrollment":478,"conditions":479,"interventions":481},[94],"2026-12","2025-04",288,[480,35],"Osteoarthritis Knee",[72],{"intervention":57,"totalTrials":120,"cells":483},{"EARLY_PHASE1":484,"PHASE1":486,"PHASE2":488,"PHASE3":490,"PHASE4":492,"NA":494},{"trials":485,"activeCount":102},[],{"trials":487,"activeCount":102},[],{"trials":489,"activeCount":102},[],{"trials":491,"activeCount":102},[],{"trials":493,"activeCount":102},[],{"trials":495,"activeCount":120,"soonestReadout":56},[496],{"nctId":54,"briefTitle":55,"status":145,"phases":497,"primaryCompletion":56,"completion":56,"start":498,"enrollment":499,"conditions":500,"interventions":504},[94],"2019-08-05",195,[501,502,503],"Postmenopausal Atrophic Vaginitis","Postmenopausal Symptoms","Genitourinary Symptoms",[57],{"intervention":62,"totalTrials":120,"cells":506},{"EARLY_PHASE1":507,"PHASE1":509,"PHASE2":511,"PHASE3":513,"PHASE4":515,"NA":517},{"trials":508,"activeCount":102},[],{"trials":510,"activeCount":102},[],{"trials":512,"activeCount":102},[],{"trials":514,"activeCount":102},[],{"trials":516,"activeCount":102},[],{"trials":518,"activeCount":120,"soonestReadout":61},[519],{"nctId":59,"briefTitle":60,"status":145,"phases":520,"primaryCompletion":61,"completion":61,"start":521,"enrollment":499,"conditions":522,"interventions":526},[94],"2019-09-30",[523,524,525],"Vaginal Atrophy","Vulva; Atrophy","Breast Cancer",[62],{"intervention":47,"totalTrials":120,"cells":528},{"EARLY_PHASE1":529,"PHASE1":531,"PHASE2":533,"PHASE3":535,"PHASE4":537,"NA":539},{"trials":530,"activeCount":102},[],{"trials":532,"activeCount":102},[],{"trials":534,"activeCount":102},[],{"trials":536,"activeCount":102},[],{"trials":538,"activeCount":102},[],{"trials":540,"activeCount":120,"soonestReadout":46},[541],{"nctId":44,"briefTitle":45,"status":145,"phases":542,"primaryCompletion":46,"completion":543,"start":544,"enrollment":545,"conditions":546,"interventions":549},[],"2026-10-31","2023-09-01",2500,[352,547,548],"Drug","Resistance",[47],{"intervention":551,"totalTrials":98,"cells":552},"Sildenafil citrate",{"EARLY_PHASE1":553,"PHASE1":555,"PHASE2":557,"PHASE3":559,"PHASE4":574,"NA":583},{"trials":554,"activeCount":102},[],{"trials":556,"activeCount":102},[],{"trials":558,"activeCount":102},[],{"trials":560,"activeCount":102},[561],{"nctId":562,"briefTitle":563,"status":248,"phases":564,"primaryCompletion":565,"completion":565,"start":566,"enrollment":567,"conditions":568,"interventions":573},"NCT01347008","Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis",[92],"2013-01","2011-04",41,[569,570,571,572],"Scleroderma, Systemic","Scleroderma, Diffuse","Scleroderma, Limited","Raynaud Phenomenon",[551],{"trials":575,"activeCount":102},[576],{"nctId":577,"briefTitle":578,"status":248,"phases":579,"enrollment":349,"conditions":580,"interventions":582},"NCT01153204","Satisfaction, Confidence and Naturalness in Men With Psychogenic Erectile Dysfunction (ED)",[93],[581],"Erectile Dysfunction",[551],{"trials":584,"activeCount":102},[],{"intervention":230,"totalTrials":98,"cells":586},{"EARLY_PHASE1":587,"PHASE1":589,"PHASE2":591,"PHASE3":605,"PHASE4":607,"NA":613},{"trials":588,"activeCount":102},[],{"trials":590,"activeCount":102},[],{"trials":592,"activeCount":102},[593],{"nctId":594,"briefTitle":595,"status":248,"phases":596,"primaryCompletion":597,"completion":598,"start":599,"enrollment":600,"conditions":601,"interventions":603},"NCT05092152","Propofol Versus Ketamine for Rapid Sequence Intubation in Critically Ill Patients",[91],"2023-10-31","2023-12-31","2021-10-23",207,[602],"Acute Respiratory Failure",[604,230],"Esketamine",{"trials":606,"activeCount":102},[],{"trials":608,"activeCount":102},[609],{"nctId":219,"briefTitle":220,"status":221,"phases":610,"primaryCompletion":223,"completion":224,"start":225,"enrollment":226,"conditions":611,"interventions":612},[93],[228],[230,194,231],{"trials":614,"activeCount":102},[],{"intervention":616,"totalTrials":98,"cells":617},"Tramadol",{"EARLY_PHASE1":618,"PHASE1":620,"PHASE2":622,"PHASE3":624,"PHASE4":638,"NA":651},{"trials":619,"activeCount":102},[],{"trials":621,"activeCount":102},[],{"trials":623,"activeCount":102},[],{"trials":625,"activeCount":102},[626],{"nctId":627,"briefTitle":628,"status":248,"phases":629,"primaryCompletion":630,"completion":630,"start":631,"enrollment":632,"conditions":633,"interventions":636},"NCT00713726","Tramadol Versus Fentanyl for Post-Operative Analgesia in Newborn Infants",[92],"2008-07","2006-01",160,[24,634,635],"Neonatal Infections","Analgesia",[637,616],"FentanyL",{"trials":639,"activeCount":102},[640],{"nctId":641,"briefTitle":642,"status":248,"phases":643,"primaryCompletion":644,"completion":644,"start":250,"enrollment":149,"conditions":645,"interventions":648},"NCT01943760","Tamadol Wound Infiltration in Children Under Inguinal Hernioplasty",[93],"2013-09",[646,647],"Children","Inguinal Hernia",[649,650],"tramadol","0.9% saline",{"trials":652,"activeCount":102},[],{"intervention":654,"totalTrials":98,"cells":655},"oral isotretinoin",{"EARLY_PHASE1":656,"PHASE1":658,"PHASE2":660,"PHASE3":675,"PHASE4":677,"NA":693},{"trials":657,"activeCount":102},[],{"trials":659,"activeCount":102},[],{"trials":661,"activeCount":102},[662],{"nctId":663,"briefTitle":664,"status":221,"phases":665,"primaryCompletion":666,"completion":667,"start":668,"enrollment":669,"conditions":670,"interventions":673},"NCT00842907","Efficacy and Safety of Oral Isotretinoin for Cutaneous Photodamage",[91],"2009-12","2010-08","2009-05",20,[671,672],"Photodamage","Photoaging",[654,674],"Tretinoin",{"trials":676,"activeCount":102},[],{"trials":678,"activeCount":102},[679],{"nctId":680,"briefTitle":681,"status":221,"phases":682,"primaryCompletion":683,"completion":684,"start":685,"enrollment":686,"conditions":687,"interventions":691},"NCT01139749","Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea",[93],"2012-07","2012-12","2011-10",50,[688,689,690],"Seborrhea","Seborrheic Dermatitis","Quality of Life",[654,692],"salicylic acid and ciclopirox olamine",{"trials":694,"activeCount":102},[],{"intervention":696,"totalTrials":120,"cells":697},"Topiramate",{"EARLY_PHASE1":698,"PHASE1":700,"PHASE2":702,"PHASE3":704,"PHASE4":706,"NA":717},{"trials":699,"activeCount":102},[],{"trials":701,"activeCount":102},[],{"trials":703,"activeCount":102},[],{"trials":705,"activeCount":102},[],{"trials":707,"activeCount":102},[708],{"nctId":709,"briefTitle":710,"status":248,"phases":711,"primaryCompletion":224,"completion":666,"start":712,"enrollment":713,"conditions":714,"interventions":716},"NCT00725920","Placebo Controled Clinical Trial Using Topiramate To Treat Posttraumatic Stress Disorder (PTSD) Patients.",[93],"2007-01",35,[715],"Posttraumatic Stress Disorder",[696],{"trials":718,"activeCount":102},[],{"intervention":720,"totalTrials":120,"cells":721},"cyanoacrylate",{"EARLY_PHASE1":722,"PHASE1":724,"PHASE2":726,"PHASE3":728,"PHASE4":730,"NA":743},{"trials":723,"activeCount":102},[],{"trials":725,"activeCount":102},[],{"trials":727,"activeCount":102},[],{"trials":729,"activeCount":102},[],{"trials":731,"activeCount":102},[732],{"nctId":733,"briefTitle":734,"status":248,"phases":735,"primaryCompletion":736,"completion":737,"start":738,"enrollment":739,"conditions":740,"interventions":742},"NCT00799851","A Randomized Controlled Trial Comparing Band Ligation and Cyanoacrylate Injection for Esophageal Varices",[93],"2007-05","2007-08","2004-11",38,[741],"Liver Disease",[720],{"trials":744,"activeCount":102},[],{"intervention":746,"totalTrials":120,"cells":747},"brimonidine",{"EARLY_PHASE1":748,"PHASE1":750,"PHASE2":752,"PHASE3":754,"PHASE4":756,"NA":765},{"trials":749,"activeCount":102},[],{"trials":751,"activeCount":102},[],{"trials":753,"activeCount":102},[],{"trials":755,"activeCount":102},[],{"trials":757,"activeCount":102},[758],{"nctId":759,"briefTitle":760,"status":761,"phases":762,"conditions":763,"interventions":764},"NCT00347035","INFLUENCE OF TOPICAL INDOMETHACIN ON HYPOTHENSIVE EFFECT OF BRIMONIDINE","TERMINATED",[93],[151],[746],{"trials":766,"activeCount":102},[],{"intervention":768,"totalTrials":120,"cells":769},"dexter ketamine",{"EARLY_PHASE1":770,"PHASE1":772,"PHASE2":774,"PHASE3":776,"PHASE4":778,"NA":806},{"trials":771,"activeCount":102},[],{"trials":773,"activeCount":102},[],{"trials":775,"activeCount":102},[],{"trials":777,"activeCount":102},[],{"trials":779,"activeCount":102},[780],{"nctId":781,"briefTitle":782,"status":221,"phases":783,"primaryCompletion":784,"completion":785,"start":784,"enrollment":149,"conditions":786,"interventions":793},"NCT02953210","Laparoscopic Cholecystectomy: General Anesthesia With Opioid Versus General Opioid Free Anesthesia",[93],"2016-11","2017-03",[787,788,789,790,791,792],"Pain, Postoperative","Anesthesia Complication","Nausea","Vomiting","Ileus Paralytic","Hemodynamic Instability",[768,794,795,796,797,798,799,800,801,802,803,804,805],"Lidocaine Hydrochloride","Fentanyl Hydrochloride","Clonidine Hydrochloride","Midazolam Hydrochloride","Isoflurane Volatile Liquid","Rocuronium Injectable Solution","Propofol 1 % Injectable Suspension","Dexamethasone-21-Sulfobenzoate, Sodium Salt","Ranitidine Hydrochloride","Ondansetron Hydrochloride","Ketorolac Injectable Solution","Bupivacaine Hydrochloride",{"trials":807,"activeCount":102},[],{"intervention":794,"totalTrials":120,"cells":809},{"EARLY_PHASE1":810,"PHASE1":812,"PHASE2":814,"PHASE3":816,"PHASE4":818,"NA":824},{"trials":811,"activeCount":102},[],{"trials":813,"activeCount":102},[],{"trials":815,"activeCount":102},[],{"trials":817,"activeCount":102},[],{"trials":819,"activeCount":102},[820],{"nctId":781,"briefTitle":782,"status":221,"phases":821,"primaryCompletion":784,"completion":785,"start":784,"enrollment":149,"conditions":822,"interventions":823},[93],[787,788,789,790,791,792],[768,794,795,796,797,798,799,800,801,802,803,804,805],{"trials":825,"activeCount":102},[],{"intervention":795,"totalTrials":120,"cells":827},{"EARLY_PHASE1":828,"PHASE1":830,"PHASE2":832,"PHASE3":834,"PHASE4":836,"NA":842},{"trials":829,"activeCount":102},[],{"trials":831,"activeCount":102},[],{"trials":833,"activeCount":102},[],{"trials":835,"activeCount":102},[],{"trials":837,"activeCount":102},[838],{"nctId":781,"briefTitle":782,"status":221,"phases":839,"primaryCompletion":784,"completion":785,"start":784,"enrollment":149,"conditions":840,"interventions":841},[93],[787,788,789,790,791,792],[768,794,795,796,797,798,799,800,801,802,803,804,805],{"trials":843,"activeCount":102},[],{"intervention":796,"totalTrials":120,"cells":845},{"EARLY_PHASE1":846,"PHASE1":848,"PHASE2":850,"PHASE3":852,"PHASE4":854,"NA":860},{"trials":847,"activeCount":102},[],{"trials":849,"activeCount":102},[],{"trials":851,"activeCount":102},[],{"trials":853,"activeCount":102},[],{"trials":855,"activeCount":102},[856],{"nctId":781,"briefTitle":782,"status":221,"phases":857,"primaryCompletion":784,"completion":785,"start":784,"enrollment":149,"conditions":858,"interventions":859},[93],[787,788,789,790,791,792],[768,794,795,796,797,798,799,800,801,802,803,804,805],{"trials":861,"activeCount":102},[],{"intervention":797,"totalTrials":120,"cells":863},{"EARLY_PHASE1":864,"PHASE1":866,"PHASE2":868,"PHASE3":870,"PHASE4":872,"NA":878},{"trials":865,"activeCount":102},[],{"trials":867,"activeCount":102},[],{"trials":869,"activeCount":102},[],{"trials":871,"activeCount":102},[],{"trials":873,"activeCount":102},[874],{"nctId":781,"briefTitle":782,"status":221,"phases":875,"primaryCompletion":784,"completion":785,"start":784,"enrollment":149,"conditions":876,"interventions":877},[93],[787,788,789,790,791,792],[768,794,795,796,797,798,799,800,801,802,803,804,805],{"trials":879,"activeCount":102},[],{"intervention":798,"totalTrials":120,"cells":881},{"EARLY_PHASE1":882,"PHASE1":884,"PHASE2":886,"PHASE3":888,"PHASE4":890,"NA":896},{"trials":883,"activeCount":102},[],{"trials":885,"activeCount":102},[],{"trials":887,"activeCount":102},[],{"trials":889,"activeCount":102},[],{"trials":891,"activeCount":102},[892],{"nctId":781,"briefTitle":782,"status":221,"phases":893,"primaryCompletion":784,"completion":785,"start":784,"enrollment":149,"conditions":894,"interventions":895},[93],[787,788,789,790,791,792],[768,794,795,796,797,798,799,800,801,802,803,804,805],{"trials":897,"activeCount":102},[],{"intervention":799,"totalTrials":120,"cells":899},{"EARLY_PHASE1":900,"PHASE1":902,"PHASE2":904,"PHASE3":906,"PHASE4":908,"NA":914},{"trials":901,"activeCount":102},[],{"trials":903,"activeCount":102},[],{"trials":905,"activeCount":102},[],{"trials":907,"activeCount":102},[],{"trials":909,"activeCount":102},[910],{"nctId":781,"briefTitle":782,"status":221,"phases":911,"primaryCompletion":784,"completion":785,"start":784,"enrollment":149,"conditions":912,"interventions":913},[93],[787,788,789,790,791,792],[768,794,795,796,797,798,799,800,801,802,803,804,805],{"trials":915,"activeCount":102},[],{"intervention":800,"totalTrials":120,"cells":917},{"EARLY_PHASE1":918,"PHASE1":920,"PHASE2":922,"PHASE3":924,"PHASE4":926,"NA":932},{"trials":919,"activeCount":102},[],{"trials":921,"activeCount":102},[],{"trials":923,"activeCount":102},[],{"trials":925,"activeCount":102},[],{"trials":927,"activeCount":102},[928],{"nctId":781,"briefTitle":782,"status":221,"phases":929,"primaryCompletion":784,"completion":785,"start":784,"enrollment":149,"conditions":930,"interventions":931},[93],[787,788,789,790,791,792],[768,794,795,796,797,798,799,800,801,802,803,804,805],{"trials":933,"activeCount":102},[],{"intervention":801,"totalTrials":120,"cells":935},{"EARLY_PHASE1":936,"PHASE1":938,"PHASE2":940,"PHASE3":942,"PHASE4":944,"NA":950},{"trials":937,"activeCount":102},[],{"trials":939,"activeCount":102},[],{"trials":941,"activeCount":102},[],{"trials":943,"activeCount":102},[],{"trials":945,"activeCount":102},[946],{"nctId":781,"briefTitle":782,"status":221,"phases":947,"primaryCompletion":784,"completion":785,"start":784,"enrollment":149,"conditions":948,"interventions":949},[93],[787,788,789,790,791,792],[768,794,795,796,797,798,799,800,801,802,803,804,805],{"trials":951,"activeCount":102},[],{"intervention":802,"totalTrials":120,"cells":953},{"EARLY_PHASE1":954,"PHASE1":956,"PHASE2":958,"PHASE3":960,"PHASE4":962,"NA":968},{"trials":955,"activeCount":102},[],{"trials":957,"activeCount":102},[],{"trials":959,"activeCount":102},[],{"trials":961,"activeCount":102},[],{"trials":963,"activeCount":102},[964],{"nctId":781,"briefTitle":782,"status":221,"phases":965,"primaryCompletion":784,"completion":785,"start":784,"enrollment":149,"conditions":966,"interventions":967},[93],[787,788,789,790,791,792],[768,794,795,796,797,798,799,800,801,802,803,804,805],{"trials":969,"activeCount":102},[],{"intervention":803,"totalTrials":120,"cells":971},{"EARLY_PHASE1":972,"PHASE1":974,"PHASE2":976,"PHASE3":978,"PHASE4":980,"NA":986},{"trials":973,"activeCount":102},[],{"trials":975,"activeCount":102},[],{"trials":977,"activeCount":102},[],{"trials":979,"activeCount":102},[],{"trials":981,"activeCount":102},[982],{"nctId":781,"briefTitle":782,"status":221,"phases":983,"primaryCompletion":784,"completion":785,"start":784,"enrollment":149,"conditions":984,"interventions":985},[93],[787,788,789,790,791,792],[768,794,795,796,797,798,799,800,801,802,803,804,805],{"trials":987,"activeCount":102},[],{"intervention":804,"totalTrials":120,"cells":989},{"EARLY_PHASE1":990,"PHASE1":992,"PHASE2":994,"PHASE3":996,"PHASE4":998,"NA":1004},{"trials":991,"activeCount":102},[],{"trials":993,"activeCount":102},[],{"trials":995,"activeCount":102},[],{"trials":997,"activeCount":102},[],{"trials":999,"activeCount":102},[1000],{"nctId":781,"briefTitle":782,"status":221,"phases":1001,"primaryCompletion":784,"completion":785,"start":784,"enrollment":149,"conditions":1002,"interventions":1003},[93],[787,788,789,790,791,792],[768,794,795,796,797,798,799,800,801,802,803,804,805],{"trials":1005,"activeCount":102},[],{"intervention":805,"totalTrials":120,"cells":1007},{"EARLY_PHASE1":1008,"PHASE1":1010,"PHASE2":1012,"PHASE3":1014,"PHASE4":1016,"NA":1022},{"trials":1009,"activeCount":102},[],{"trials":1011,"activeCount":102},[],{"trials":1013,"activeCount":102},[],{"trials":1015,"activeCount":102},[],{"trials":1017,"activeCount":102},[1018],{"nctId":781,"briefTitle":782,"status":221,"phases":1019,"primaryCompletion":784,"completion":785,"start":784,"enrollment":149,"conditions":1020,"interventions":1021},[93],[787,788,789,790,791,792],[768,794,795,796,797,798,799,800,801,802,803,804,805],{"trials":1023,"activeCount":102},[],{"intervention":1025,"totalTrials":120,"cells":1026},"Loteprednol Etabonate 0.5%",{"EARLY_PHASE1":1027,"PHASE1":1029,"PHASE2":1031,"PHASE3":1033,"PHASE4":1035,"NA":1049},{"trials":1028,"activeCount":102},[],{"trials":1030,"activeCount":102},[],{"trials":1032,"activeCount":102},[],{"trials":1034,"activeCount":102},[],{"trials":1036,"activeCount":102},[1037],{"nctId":1038,"briefTitle":1039,"status":248,"phases":1040,"primaryCompletion":1041,"completion":1042,"start":1043,"enrollment":713,"conditions":1044,"interventions":1047},"NCT00781300","Intraocular Pressure With Loteprednol and Dexamethasone",[93],"2006-11","2007-02","2006-03",[1045,1046],"Glaucoma, Open-Angle","Ocular Hypertension",[1025,1048],"Dexamethasone 0.1%",{"trials":1050,"activeCount":102},[],{"intervention":1048,"totalTrials":120,"cells":1052},{"EARLY_PHASE1":1053,"PHASE1":1055,"PHASE2":1057,"PHASE3":1059,"PHASE4":1061,"NA":1067},{"trials":1054,"activeCount":102},[],{"trials":1056,"activeCount":102},[],{"trials":1058,"activeCount":102},[],{"trials":1060,"activeCount":102},[],{"trials":1062,"activeCount":102},[1063],{"nctId":1038,"briefTitle":1039,"status":248,"phases":1064,"primaryCompletion":1041,"completion":1042,"start":1043,"enrollment":713,"conditions":1065,"interventions":1066},[93],[1045,1046],[1025,1048],{"trials":1068,"activeCount":102},[],{"intervention":1070,"totalTrials":120,"cells":1071},"Ranibizumab",{"EARLY_PHASE1":1072,"PHASE1":1074,"PHASE2":1076,"PHASE3":1078,"PHASE4":1080,"NA":1092},{"trials":1073,"activeCount":102},[],{"trials":1075,"activeCount":102},[],{"trials":1077,"activeCount":102},[],{"trials":1079,"activeCount":102},[],{"trials":1081,"activeCount":102},[1082],{"nctId":1083,"briefTitle":1084,"status":1085,"phases":1086,"primaryCompletion":1087,"completion":348,"start":1088,"enrollment":102,"conditions":1089,"interventions":1091},"NCT02055911","Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema","WITHDRAWN",[93],"2015-03","2014-03",[1090],"Diabetic Macular Edema",[1070],{"trials":1093,"activeCount":102},[],{"intervention":1095,"totalTrials":120,"cells":1096},"Rosuvastatin plus clopidogrel",{"EARLY_PHASE1":1097,"PHASE1":1099,"PHASE2":1101,"PHASE3":1103,"PHASE4":1105,"NA":1120},{"trials":1098,"activeCount":102},[],{"trials":1100,"activeCount":102},[],{"trials":1102,"activeCount":102},[],{"trials":1104,"activeCount":102},[],{"trials":1106,"activeCount":102},[1107],{"nctId":1108,"briefTitle":1109,"status":221,"phases":1110,"primaryCompletion":1111,"completion":1112,"start":1113,"enrollment":12,"conditions":1114,"interventions":1116},"NCT02428374","Role of Immune Responses After Acute Myocardial Infarction",[93],"2018-04","2019-07","2015-05",[1115],"Myocardial Fibrosis",[1095,1117,1118,1119],"Rosuvastatin plus ticagrelor","Simvastatin plus clopidogrel","Simvastatin plus ticagrelor",{"trials":1121,"activeCount":102},[],{"intervention":1117,"totalTrials":120,"cells":1123},{"EARLY_PHASE1":1124,"PHASE1":1126,"PHASE2":1128,"PHASE3":1130,"PHASE4":1132,"NA":1138},{"trials":1125,"activeCount":102},[],{"trials":1127,"activeCount":102},[],{"trials":1129,"activeCount":102},[],{"trials":1131,"activeCount":102},[],{"trials":1133,"activeCount":102},[1134],{"nctId":1108,"briefTitle":1109,"status":221,"phases":1135,"primaryCompletion":1111,"completion":1112,"start":1113,"enrollment":12,"conditions":1136,"interventions":1137},[93],[1115],[1095,1117,1118,1119],{"trials":1139,"activeCount":102},[],{"intervention":1118,"totalTrials":120,"cells":1141},{"EARLY_PHASE1":1142,"PHASE1":1144,"PHASE2":1146,"PHASE3":1148,"PHASE4":1150,"NA":1156},{"trials":1143,"activeCount":102},[],{"trials":1145,"activeCount":102},[],{"trials":1147,"activeCount":102},[],{"trials":1149,"activeCount":102},[],{"trials":1151,"activeCount":102},[1152],{"nctId":1108,"briefTitle":1109,"status":221,"phases":1153,"primaryCompletion":1111,"completion":1112,"start":1113,"enrollment":12,"conditions":1154,"interventions":1155},[93],[1115],[1095,1117,1118,1119],{"trials":1157,"activeCount":102},[],{"intervention":1119,"totalTrials":120,"cells":1159},{"EARLY_PHASE1":1160,"PHASE1":1162,"PHASE2":1164,"PHASE3":1166,"PHASE4":1168,"NA":1174},{"trials":1161,"activeCount":102},[],{"trials":1163,"activeCount":102},[],{"trials":1165,"activeCount":102},[],{"trials":1167,"activeCount":102},[],{"trials":1169,"activeCount":102},[1170],{"nctId":1108,"briefTitle":1109,"status":221,"phases":1171,"primaryCompletion":1111,"completion":1112,"start":1113,"enrollment":12,"conditions":1172,"interventions":1173},[93],[1115],[1095,1117,1118,1119],{"trials":1175,"activeCount":102},[],{"intervention":1177,"totalTrials":120,"cells":1178},"Formoterol plus Placebo",{"EARLY_PHASE1":1179,"PHASE1":1181,"PHASE2":1183,"PHASE3":1185,"PHASE4":1187,"NA":1203},{"trials":1180,"activeCount":102},[],{"trials":1182,"activeCount":102},[],{"trials":1184,"activeCount":102},[],{"trials":1186,"activeCount":102},[],{"trials":1188,"activeCount":102},[1189],{"nctId":1190,"briefTitle":1191,"status":248,"phases":1192,"primaryCompletion":1193,"completion":1194,"start":1195,"enrollment":1196,"conditions":1197,"interventions":1201},"NCT00680056","Add-on Effects of Tiotropium Over Formoterol in Exercise Tolerance on Chronic Obstructive Pulmonary Disease Patients",[93],"2008-12","2009-01","2007-11",33,[1198,1199,1200],"Pulmonary Disease, Chronic Obstructive","Chronic Bronchitis","Pulmonary Emphysema",[1177,1202],"Formoterol plus Tiotropium",{"trials":1204,"activeCount":102},[],{"intervention":1202,"totalTrials":120,"cells":1206},{"EARLY_PHASE1":1207,"PHASE1":1209,"PHASE2":1211,"PHASE3":1213,"PHASE4":1215,"NA":1221},{"trials":1208,"activeCount":102},[],{"trials":1210,"activeCount":102},[],{"trials":1212,"activeCount":102},[],{"trials":1214,"activeCount":102},[],{"trials":1216,"activeCount":102},[1217],{"nctId":1190,"briefTitle":1191,"status":248,"phases":1218,"primaryCompletion":1193,"completion":1194,"start":1195,"enrollment":1196,"conditions":1219,"interventions":1220},[93],[1198,1199,1200],[1177,1202],{"trials":1222,"activeCount":102},[],{"intervention":1224,"totalTrials":120,"cells":1225},"norepinephrine",{"EARLY_PHASE1":1226,"PHASE1":1228,"PHASE2":1230,"PHASE3":1232,"PHASE4":1234,"NA":1245},{"trials":1227,"activeCount":102},[],{"trials":1229,"activeCount":102},[],{"trials":1231,"activeCount":102},[],{"trials":1233,"activeCount":102},[],{"trials":1235,"activeCount":102},[1236],{"nctId":1237,"briefTitle":1238,"status":248,"phases":1239,"primaryCompletion":784,"completion":1240,"start":1241,"enrollment":149,"conditions":1242,"interventions":1244},"NCT02519699","Microcirculation After MAP Increase in Septic Shock Patients With Previous Hypertension",[93],"2017-01","2013-03",[1243],"Septic Shock",[1224],{"trials":1246,"activeCount":102},[],{"intervention":1248,"totalTrials":120,"cells":1249},"Intra-articular injection with corticosteroid",{"EARLY_PHASE1":1250,"PHASE1":1252,"PHASE2":1254,"PHASE3":1256,"PHASE4":1258,"NA":1271},{"trials":1251,"activeCount":102},[],{"trials":1253,"activeCount":102},[],{"trials":1255,"activeCount":102},[],{"trials":1257,"activeCount":102},[],{"trials":1259,"activeCount":102},[1260],{"nctId":1261,"briefTitle":1262,"status":248,"phases":1263,"primaryCompletion":1264,"completion":1265,"start":1266,"enrollment":210,"conditions":1267,"interventions":1269},"NCT02102620","Corticosteroid Intra-articular Injection in Hands Osteoarthritis",[93],"2012-08","2013-06","2011-08",[1268],"Hands Osteoarthritis",[1248,1270],"Intra-articular injection with lidocaine",{"trials":1272,"activeCount":102},[],{"intervention":1270,"totalTrials":120,"cells":1274},{"EARLY_PHASE1":1275,"PHASE1":1277,"PHASE2":1279,"PHASE3":1281,"PHASE4":1283,"NA":1289},{"trials":1276,"activeCount":102},[],{"trials":1278,"activeCount":102},[],{"trials":1280,"activeCount":102},[],{"trials":1282,"activeCount":102},[],{"trials":1284,"activeCount":102},[1285],{"nctId":1261,"briefTitle":1262,"status":248,"phases":1286,"primaryCompletion":1264,"completion":1265,"start":1266,"enrollment":210,"conditions":1287,"interventions":1288},[93],[1268],[1248,1270],{"trials":1290,"activeCount":102},[],{"intervention":1292,"totalTrials":120,"cells":1293},"PROPRANOLOL",{"EARLY_PHASE1":1294,"PHASE1":1296,"PHASE2":1298,"PHASE3":1300,"PHASE4":1302,"NA":1315},{"trials":1295,"activeCount":102},[],{"trials":1297,"activeCount":102},[],{"trials":1299,"activeCount":102},[],{"trials":1301,"activeCount":102},[],{"trials":1303,"activeCount":102},[1304],{"nctId":1305,"briefTitle":1306,"status":248,"phases":1307,"primaryCompletion":1308,"completion":1308,"start":1309,"enrollment":1310,"conditions":1311,"interventions":1314},"NCT01893541","PROPRANOLOL PLUS LIGATION REDUCES RECURRENCE OF ESOPHAGEAL VARICES?",[93],"2011-06","2008-06",100,[1312,1313],"CIRRHOSIS","ESOPHAGEAL VARICES",[1292],{"trials":1316,"activeCount":102},[],{"intervention":1318,"totalTrials":120,"cells":1319},"Acetylsalicylic acid",{"EARLY_PHASE1":1320,"PHASE1":1322,"PHASE2":1324,"PHASE3":1326,"PHASE4":1328,"NA":1340},{"trials":1321,"activeCount":102},[],{"trials":1323,"activeCount":102},[],{"trials":1325,"activeCount":102},[],{"trials":1327,"activeCount":102},[],{"trials":1329,"activeCount":102},[1330],{"nctId":1331,"briefTitle":1332,"status":248,"phases":1333,"primaryCompletion":1334,"completion":1335,"start":1336,"enrollment":327,"conditions":1337,"interventions":1339},"NCT03558854","Evaluation of Effectiveness of Acetylsalicylic Acid on Markers of Vascular Dysfunction in Scleroderma Patients",[93],"2021-09-02","2021-10-26","2018-08-28",[1338],"Systemic Sclerosis",[1318],{"trials":1341,"activeCount":102},[],{"intervention":1343,"totalTrials":120,"cells":1344},"Methotrexate",{"EARLY_PHASE1":1345,"PHASE1":1347,"PHASE2":1349,"PHASE3":1351,"PHASE4":1353,"NA":1364},{"trials":1346,"activeCount":102},[],{"trials":1348,"activeCount":102},[],{"trials":1350,"activeCount":102},[],{"trials":1352,"activeCount":102},[],{"trials":1354,"activeCount":102},[1355],{"nctId":1356,"briefTitle":1357,"status":248,"phases":1358,"primaryCompletion":565,"completion":1265,"start":1359,"enrollment":1360,"conditions":1361,"interventions":1363},"NCT01876004","Effectiveness Of Expectant Management In The Tubal Ectopic Pregnancy",[93],"2011-09",25,[1362],"Ectopic Pregnancy",[1343],{"trials":1365,"activeCount":102},[],{"intervention":1367,"totalTrials":120,"cells":1368},"Intraocular Instillation Solution",{"EARLY_PHASE1":1369,"PHASE1":1371,"PHASE2":1373,"PHASE3":1375,"PHASE4":1377,"NA":1391},{"trials":1370,"activeCount":102},[],{"trials":1372,"activeCount":102},[],{"trials":1374,"activeCount":102},[],{"trials":1376,"activeCount":102},[],{"trials":1378,"activeCount":102},[1379],{"nctId":1380,"briefTitle":1381,"status":221,"phases":1382,"primaryCompletion":1383,"completion":1384,"start":1385,"enrollment":1310,"conditions":1386,"interventions":1389},"NCT05079854","Use Of Intracameral Moxifloxacin For Prophylaxis Of Open Globe Endophthalmitis",[93],"2022-11-01","2023-11-01","2021-10-01",[1387,1388],"Endophthalmitis","Trauma, Corneal",[1367,1390],"Moxifloxacin Ophthalmic",{"trials":1392,"activeCount":102},[],{"intervention":1390,"totalTrials":120,"cells":1394},{"EARLY_PHASE1":1395,"PHASE1":1397,"PHASE2":1399,"PHASE3":1401,"PHASE4":1403,"NA":1409},{"trials":1396,"activeCount":102},[],{"trials":1398,"activeCount":102},[],{"trials":1400,"activeCount":102},[],{"trials":1402,"activeCount":102},[],{"trials":1404,"activeCount":102},[1405],{"nctId":1380,"briefTitle":1381,"status":221,"phases":1406,"primaryCompletion":1383,"completion":1384,"start":1385,"enrollment":1310,"conditions":1407,"interventions":1408},[93],[1387,1388],[1367,1390],{"trials":1410,"activeCount":102},[],{"intervention":650,"totalTrials":120,"cells":1412},{"EARLY_PHASE1":1413,"PHASE1":1415,"PHASE2":1417,"PHASE3":1419,"PHASE4":1421,"NA":1427},{"trials":1414,"activeCount":102},[],{"trials":1416,"activeCount":102},[],{"trials":1418,"activeCount":102},[],{"trials":1420,"activeCount":102},[],{"trials":1422,"activeCount":102},[1423],{"nctId":641,"briefTitle":642,"status":248,"phases":1424,"primaryCompletion":644,"completion":644,"start":250,"enrollment":149,"conditions":1425,"interventions":1426},[93],[646,647],[649,650],{"trials":1428,"activeCount":102},[],{"intervention":1430,"totalTrials":120,"cells":1431},"Restasis",{"EARLY_PHASE1":1432,"PHASE1":1434,"PHASE2":1436,"PHASE3":1438,"PHASE4":1440,"NA":1454},{"trials":1433,"activeCount":102},[],{"trials":1435,"activeCount":102},[],{"trials":1437,"activeCount":102},[],{"trials":1439,"activeCount":102},[],{"trials":1441,"activeCount":102},[1442],{"nctId":1443,"briefTitle":1444,"status":248,"phases":1445,"primaryCompletion":1446,"completion":1446,"start":565,"enrollment":1310,"conditions":1447,"interventions":1452},"NCT02004067","Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease",[93],"2016-08",[1448,1449,1450,1451],"Primary Sjogren Syndrome","Secondary Sjogren Syndrome","Aqueous Deficient Dry Eye Disease","Evaporative Dry Eye Disease",[1430,1453],"Refresh Endura",{"trials":1455,"activeCount":102},[],{"intervention":1453,"totalTrials":120,"cells":1457},{"EARLY_PHASE1":1458,"PHASE1":1460,"PHASE2":1462,"PHASE3":1464,"PHASE4":1466,"NA":1472},{"trials":1459,"activeCount":102},[],{"trials":1461,"activeCount":102},[],{"trials":1463,"activeCount":102},[],{"trials":1465,"activeCount":102},[],{"trials":1467,"activeCount":102},[1468],{"nctId":1443,"briefTitle":1444,"status":248,"phases":1469,"primaryCompletion":1446,"completion":1446,"start":565,"enrollment":1310,"conditions":1470,"interventions":1471},[93],[1448,1449,1450,1451],[1430,1453],{"trials":1473,"activeCount":102},[],{"intervention":1475,"totalTrials":120,"cells":1476},"Homeopathic medication Plumbum metallicum",{"EARLY_PHASE1":1477,"PHASE1":1479,"PHASE2":1481,"PHASE3":1483,"PHASE4":1485,"NA":1495},{"trials":1478,"activeCount":102},[],{"trials":1480,"activeCount":102},[],{"trials":1482,"activeCount":102},[],{"trials":1484,"activeCount":102},[],{"trials":1486,"activeCount":102},[1487],{"nctId":1488,"briefTitle":1489,"status":248,"phases":1490,"enrollment":1491,"conditions":1492,"interventions":1494},"NCT00931905","Homeopathic Preparation Plumbum Metallicum for Lead Poisoning",[93],113,[1493],"Lead Poisoning",[1475],{"trials":1496,"activeCount":102},[],{"intervention":1498,"totalTrials":120,"cells":1499},"Sugammadex",{"EARLY_PHASE1":1500,"PHASE1":1502,"PHASE2":1504,"PHASE3":1506,"PHASE4":1508,"NA":1519},{"trials":1501,"activeCount":102},[],{"trials":1503,"activeCount":102},[],{"trials":1505,"activeCount":102},[],{"trials":1507,"activeCount":102},[],{"trials":1509,"activeCount":102},[1510],{"nctId":1511,"briefTitle":1512,"status":248,"phases":1513,"primaryCompletion":1514,"completion":1514,"start":685,"enrollment":149,"conditions":1515,"interventions":1518},"NCT01785758","Efficacy and Safety of Sugammadex in Renal Diseased Patients",[93],"2012-01",[1516,1517],"Kidney Failure, Chronic","Neuromuscular Blockade",[1498],{"trials":1520,"activeCount":102},[],{"intervention":1522,"totalTrials":120,"cells":1523},"Prasugrel",{"EARLY_PHASE1":1524,"PHASE1":1526,"PHASE2":1528,"PHASE3":1530,"PHASE4":1532,"NA":1546},{"trials":1525,"activeCount":102},[],{"trials":1527,"activeCount":102},[],{"trials":1529,"activeCount":102},[],{"trials":1531,"activeCount":102},[],{"trials":1533,"activeCount":102},[1534],{"nctId":1535,"briefTitle":1536,"status":248,"phases":1537,"primaryCompletion":1538,"completion":1539,"start":1540,"enrollment":686,"conditions":1541,"interventions":1544},"NCT02215993","Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients Submitted to Thrombolysis",[93],"2014-09","2014-10","2013-07",[1542,1543],"Acute Coronary Syndrome","Platelet Function",[1522,1545],"Ticagrelor",{"trials":1547,"activeCount":102},[],{"intervention":1545,"totalTrials":120,"cells":1549},{"EARLY_PHASE1":1550,"PHASE1":1552,"PHASE2":1554,"PHASE3":1556,"PHASE4":1558,"NA":1564},{"trials":1551,"activeCount":102},[],{"trials":1553,"activeCount":102},[],{"trials":1555,"activeCount":102},[],{"trials":1557,"activeCount":102},[],{"trials":1559,"activeCount":102},[1560],{"nctId":1535,"briefTitle":1536,"status":248,"phases":1561,"primaryCompletion":1538,"completion":1539,"start":1540,"enrollment":686,"conditions":1562,"interventions":1563},[93],[1542,1543],[1522,1545],{"trials":1565,"activeCount":102},[],{"intervention":1567,"totalTrials":120,"cells":1568},"Vitamin D",{"EARLY_PHASE1":1569,"PHASE1":1571,"PHASE2":1573,"PHASE3":1575,"PHASE4":1577,"NA":1592},{"trials":1570,"activeCount":102},[],{"trials":1572,"activeCount":102},[],{"trials":1574,"activeCount":102},[],{"trials":1576,"activeCount":102},[],{"trials":1578,"activeCount":102},[1579],{"nctId":1580,"briefTitle":1581,"status":761,"phases":1582,"primaryCompletion":1583,"completion":1583,"start":1088,"enrollment":1584,"conditions":1585,"interventions":1590},"NCT02120274","Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C",[93],"2016-05",85,[1586,1587,1588,1589],"RNA Virus Infections","Flaviviridae Infections","Hepatitis C","Hepatitis C, Chronic",[1567,1591],"Vitamin B 12",{"trials":1593,"activeCount":102},[],{"intervention":1591,"totalTrials":120,"cells":1595},{"EARLY_PHASE1":1596,"PHASE1":1598,"PHASE2":1600,"PHASE3":1602,"PHASE4":1604,"NA":1610},{"trials":1597,"activeCount":102},[],{"trials":1599,"activeCount":102},[],{"trials":1601,"activeCount":102},[],{"trials":1603,"activeCount":102},[],{"trials":1605,"activeCount":102},[1606],{"nctId":1580,"briefTitle":1581,"status":761,"phases":1607,"primaryCompletion":1583,"completion":1583,"start":1088,"enrollment":1584,"conditions":1608,"interventions":1609},[93],[1586,1587,1588,1589],[1567,1591],{"trials":1611,"activeCount":102},[],{"intervention":1613,"totalTrials":120,"cells":1614},"prednisone",{"EARLY_PHASE1":1615,"PHASE1":1617,"PHASE2":1619,"PHASE3":1621,"PHASE4":1623,"NA":1633},{"trials":1616,"activeCount":102},[],{"trials":1618,"activeCount":102},[],{"trials":1620,"activeCount":102},[],{"trials":1622,"activeCount":102},[],{"trials":1624,"activeCount":102},[1625],{"nctId":1626,"briefTitle":1627,"status":221,"phases":1628,"primaryCompletion":225,"completion":225,"start":1629,"enrollment":327,"conditions":1630,"interventions":1632},"NCT00597064","Inflammatory, Functional and Image Composite Measure to Define Asthma Control",[93],"2006-07",[1631],"Asthma",[1613],{"trials":1634,"activeCount":102},[],{"intervention":1636,"totalTrials":120,"cells":1637},"Glatiramer acetate",{"EARLY_PHASE1":1638,"PHASE1":1640,"PHASE2":1642,"PHASE3":1644,"PHASE4":1646,"NA":1657},{"trials":1639,"activeCount":102},[],{"trials":1641,"activeCount":102},[],{"trials":1643,"activeCount":102},[],{"trials":1645,"activeCount":102},[],{"trials":1647,"activeCount":102},[1648],{"nctId":1649,"briefTitle":1650,"status":221,"phases":1651,"primaryCompletion":630,"completion":1652,"start":1629,"enrollment":349,"conditions":1653,"interventions":1655},"NCT00677664","Effects of Copaxone in the Retinal Function in Diabetic Patients After Panphotocoagulation",[93],"2008-09",[1654],"Diabetic Retinopathy",[1636,1656],"Mannitol",{"trials":1658,"activeCount":102},[],{"intervention":1656,"totalTrials":120,"cells":1660},{"EARLY_PHASE1":1661,"PHASE1":1663,"PHASE2":1665,"PHASE3":1667,"PHASE4":1669,"NA":1675},{"trials":1662,"activeCount":102},[],{"trials":1664,"activeCount":102},[],{"trials":1666,"activeCount":102},[],{"trials":1668,"activeCount":102},[],{"trials":1670,"activeCount":102},[1671],{"nctId":1649,"briefTitle":1650,"status":221,"phases":1672,"primaryCompletion":630,"completion":1652,"start":1629,"enrollment":349,"conditions":1673,"interventions":1674},[93],[1654],[1636,1656],{"trials":1676,"activeCount":102},[],{"intervention":692,"totalTrials":120,"cells":1678},{"EARLY_PHASE1":1679,"PHASE1":1681,"PHASE2":1683,"PHASE3":1685,"PHASE4":1687,"NA":1693},{"trials":1680,"activeCount":102},[],{"trials":1682,"activeCount":102},[],{"trials":1684,"activeCount":102},[],{"trials":1686,"activeCount":102},[],{"trials":1688,"activeCount":102},[1689],{"nctId":680,"briefTitle":681,"status":221,"phases":1690,"primaryCompletion":683,"completion":684,"start":685,"enrollment":686,"conditions":1691,"interventions":1692},[93],[688,689,690],[654,692],{"trials":1694,"activeCount":102},[],{"intervention":1696,"totalTrials":120,"cells":1697},"Marevan®",{"EARLY_PHASE1":1698,"PHASE1":1700,"PHASE2":1702,"PHASE3":1704,"PHASE4":1706,"NA":1718},{"trials":1699,"activeCount":102},[],{"trials":1701,"activeCount":102},[],{"trials":1703,"activeCount":102},[],{"trials":1705,"activeCount":102},[],{"trials":1707,"activeCount":102},[1708],{"nctId":1709,"briefTitle":1710,"status":248,"phases":1711,"primaryCompletion":1446,"completion":1446,"start":1712,"enrollment":1310,"conditions":1713,"interventions":1715},"NCT02017197","Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil",[93],"2014-08",[1714],"Atrial Fibrillation",[1696,1716,1717],"generic warfarin #1","generic warfarin #2",{"trials":1719,"activeCount":102},[],{"intervention":1716,"totalTrials":120,"cells":1721},{"EARLY_PHASE1":1722,"PHASE1":1724,"PHASE2":1726,"PHASE3":1728,"PHASE4":1730,"NA":1736},{"trials":1723,"activeCount":102},[],{"trials":1725,"activeCount":102},[],{"trials":1727,"activeCount":102},[],{"trials":1729,"activeCount":102},[],{"trials":1731,"activeCount":102},[1732],{"nctId":1709,"briefTitle":1710,"status":248,"phases":1733,"primaryCompletion":1446,"completion":1446,"start":1712,"enrollment":1310,"conditions":1734,"interventions":1735},[93],[1714],[1696,1716,1717],{"trials":1737,"activeCount":102},[],{"intervention":1717,"totalTrials":120,"cells":1739},{"EARLY_PHASE1":1740,"PHASE1":1742,"PHASE2":1744,"PHASE3":1746,"PHASE4":1748,"NA":1754},{"trials":1741,"activeCount":102},[],{"trials":1743,"activeCount":102},[],{"trials":1745,"activeCount":102},[],{"trials":1747,"activeCount":102},[],{"trials":1749,"activeCount":102},[1750],{"nctId":1709,"briefTitle":1710,"status":248,"phases":1751,"primaryCompletion":1446,"completion":1446,"start":1712,"enrollment":1310,"conditions":1752,"interventions":1753},[93],[1714],[1696,1716,1717],{"trials":1755,"activeCount":102},[],{"intervention":1757,"totalTrials":120,"cells":1758},"Joint injection with triamcinolone hexacetonide",{"EARLY_PHASE1":1759,"PHASE1":1761,"PHASE2":1763,"PHASE3":1765,"PHASE4":1767,"NA":1777},{"trials":1760,"activeCount":102},[],{"trials":1762,"activeCount":102},[],{"trials":1764,"activeCount":102},[],{"trials":1766,"activeCount":102},[],{"trials":1768,"activeCount":102},[1769],{"nctId":1770,"briefTitle":1771,"status":221,"phases":1772,"primaryCompletion":1773,"completion":1774,"start":1446,"enrollment":1310,"conditions":1775,"interventions":1776},"NCT02835521","Influence of Perception of Patients Suffering of Knee Osteoarthritis Regarding Effectiveness of Intra-articular Injection",[93],"2017-02","2017-07",[26],[1757],{"trials":1778,"activeCount":102},[],{"intervention":1780,"totalTrials":120,"cells":1781},"Daclatasvir + Sofosbuvir",{"EARLY_PHASE1":1782,"PHASE1":1784,"PHASE2":1786,"PHASE3":1788,"PHASE4":1790,"NA":1802},{"trials":1783,"activeCount":102},[],{"trials":1785,"activeCount":102},[],{"trials":1787,"activeCount":102},[],{"trials":1789,"activeCount":102},[],{"trials":1791,"activeCount":102},[1792],{"nctId":1793,"briefTitle":1794,"status":248,"phases":1795,"primaryCompletion":785,"completion":1796,"start":1797,"enrollment":1798,"conditions":1799,"interventions":1800},"NCT02624063","Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT)",[93],"2017-05","2015-12",121,[1589],[1780,1801],"Simeprevir + Sofosbuvir",{"trials":1803,"activeCount":102},[],{"intervention":1801,"totalTrials":120,"cells":1805},{"EARLY_PHASE1":1806,"PHASE1":1808,"PHASE2":1810,"PHASE3":1812,"PHASE4":1814,"NA":1820},{"trials":1807,"activeCount":102},[],{"trials":1809,"activeCount":102},[],{"trials":1811,"activeCount":102},[],{"trials":1813,"activeCount":102},[],{"trials":1815,"activeCount":102},[1816],{"nctId":1793,"briefTitle":1794,"status":248,"phases":1817,"primaryCompletion":785,"completion":1796,"start":1797,"enrollment":1798,"conditions":1818,"interventions":1819},[93],[1589],[1780,1801],{"trials":1821,"activeCount":102},[],{"intervention":1823,"totalTrials":1824,"cells":1825},"isoflavone",3,{"EARLY_PHASE1":1826,"PHASE1":1828,"PHASE2":1830,"PHASE3":1842,"PHASE4":1863,"NA":1865},{"trials":1827,"activeCount":102},[],{"trials":1829,"activeCount":102},[],{"trials":1831,"activeCount":102},[1832],{"nctId":1833,"briefTitle":1834,"status":248,"phases":1835,"primaryCompletion":1836,"completion":1836,"start":1837,"enrollment":349,"conditions":1838,"interventions":1840},"NCT01553773","Postmenopausal Facial Skin After Estradiol and Genistein Topical Treatment",[91],"2005-03","2004-07",[1839],"Atrophy",[1823,1841],"Estradiol",{"trials":1843,"activeCount":102},[1844,1852],{"nctId":1845,"briefTitle":1846,"status":221,"phases":1847,"primaryCompletion":1848,"start":668,"enrollment":210,"conditions":1849,"interventions":1850},"NCT00905723","The Effects of Isoflavone and Estrogen in Sex Response in Climacteric Women",[92],"2010-05",[502],[1851,1823],"estradiol",{"nctId":1853,"briefTitle":1854,"status":221,"phases":1855,"primaryCompletion":1856,"completion":667,"start":1857,"enrollment":1858,"conditions":1859,"interventions":1861},"NCT00925639","Effects of the Concentrated Extract of Soy on Coagulation Factors After Menopause",[92],"2010-01","2009-08",84,[1860],"Menopause",[1862],"Isoflavone",{"trials":1864,"activeCount":102},[],{"trials":1866,"activeCount":102},[],{"intervention":1851,"totalTrials":98,"cells":1868},{"EARLY_PHASE1":1869,"PHASE1":1871,"PHASE2":1873,"PHASE3":1879,"PHASE4":1885,"NA":1887},{"trials":1870,"activeCount":102},[],{"trials":1872,"activeCount":102},[],{"trials":1874,"activeCount":102},[1875],{"nctId":1833,"briefTitle":1834,"status":248,"phases":1876,"primaryCompletion":1836,"completion":1836,"start":1837,"enrollment":349,"conditions":1877,"interventions":1878},[91],[1839],[1823,1841],{"trials":1880,"activeCount":102},[1881],{"nctId":1845,"briefTitle":1846,"status":221,"phases":1882,"primaryCompletion":1848,"start":668,"enrollment":210,"conditions":1883,"interventions":1884},[92],[502],[1851,1823],{"trials":1886,"activeCount":102},[],{"trials":1888,"activeCount":102},[],{"intervention":1890,"totalTrials":120,"cells":1891},"5-fluoruracil",{"EARLY_PHASE1":1892,"PHASE1":1894,"PHASE2":1896,"PHASE3":1898,"PHASE4":1908,"NA":1910},{"trials":1893,"activeCount":102},[],{"trials":1895,"activeCount":102},[],{"trials":1897,"activeCount":102},[],{"trials":1899,"activeCount":102},[1900],{"nctId":1901,"briefTitle":1902,"status":221,"phases":1903,"primaryCompletion":1359,"completion":1904,"start":667,"enrollment":349,"conditions":1905,"interventions":1907},"NCT01405144","5fluorouracil for Advanced Photoaging",[92],"2012-03",[672,1906],"Actinic Keratosis",[1890],{"trials":1909,"activeCount":102},[],{"trials":1911,"activeCount":102},[],{"intervention":1913,"totalTrials":120,"cells":1914},"Omega 3",{"EARLY_PHASE1":1915,"PHASE1":1917,"PHASE2":1919,"PHASE3":1921,"PHASE4":1933,"NA":1935},{"trials":1916,"activeCount":102},[],{"trials":1918,"activeCount":102},[],{"trials":1920,"activeCount":102},[],{"trials":1922,"activeCount":102},[1923],{"nctId":1924,"briefTitle":1925,"status":248,"phases":1926,"primaryCompletion":1927,"completion":1088,"start":565,"enrollment":1928,"conditions":1929,"interventions":1932},"NCT01735279","Studying the Effects of Administration of Polyunsaturated Fatty Acids (PUFAS) of Omega-3 Series in Nicotine Dependence",[92],"2013-12",58,[1930,1931],"Tobacco Dependence","Nicotine Dependence",[1913],{"trials":1934,"activeCount":102},[],{"trials":1936,"activeCount":102},[],{"intervention":1938,"totalTrials":120,"cells":1939},"0.3% gatifloxacin and 1.0% prednisolone acetate association",{"EARLY_PHASE1":1940,"PHASE1":1942,"PHASE2":1944,"PHASE3":1946,"PHASE4":1958,"NA":1960},{"trials":1941,"activeCount":102},[],{"trials":1943,"activeCount":102},[],{"trials":1945,"activeCount":102},[],{"trials":1947,"activeCount":102},[1948],{"nctId":1949,"briefTitle":1950,"status":248,"phases":1951,"primaryCompletion":1952,"completion":1952,"start":1194,"enrollment":1953,"conditions":1954,"interventions":1956},"NCT01218737","Non-Inferiority of Gatifloxacin\u002FPrednisolone Association vs Isolated Administration in Prevention of Ocular Infection\u002FInflammation",[92],"2009-06",101,[1955],"Ocular Infection and Inflammation",[1938,1957],"isolated 0.3% gatifloxacin and 1.0% prednisolone acetate",{"trials":1959,"activeCount":102},[],{"trials":1961,"activeCount":102},[],{"intervention":1957,"totalTrials":120,"cells":1963},{"EARLY_PHASE1":1964,"PHASE1":1966,"PHASE2":1968,"PHASE3":1970,"PHASE4":1976,"NA":1978},{"trials":1965,"activeCount":102},[],{"trials":1967,"activeCount":102},[],{"trials":1969,"activeCount":102},[],{"trials":1971,"activeCount":102},[1972],{"nctId":1949,"briefTitle":1950,"status":248,"phases":1973,"primaryCompletion":1952,"completion":1952,"start":1194,"enrollment":1953,"conditions":1974,"interventions":1975},[92],[1955],[1938,1957],{"trials":1977,"activeCount":102},[],{"trials":1979,"activeCount":102},[],{"intervention":1981,"totalTrials":120,"cells":1982},"Lidocaine 2% without vessel constrictor",{"EARLY_PHASE1":1983,"PHASE1":1985,"PHASE2":1987,"PHASE3":1989,"PHASE4":2002,"NA":2004},{"trials":1984,"activeCount":102},[],{"trials":1986,"activeCount":102},[],{"trials":1988,"activeCount":102},[],{"trials":1990,"activeCount":102},[1991],{"nctId":1992,"briefTitle":1993,"status":248,"phases":1994,"primaryCompletion":1995,"completion":1996,"start":1997,"enrollment":1998,"conditions":1999,"interventions":2001},"NCT00740285","Effectiveness and Safety of Lidocaine for Scleroderma",[91,92],"2006-04","2007-04","2004-04",26,[2000],"Scleroderma",[1981],{"trials":2003,"activeCount":102},[],{"trials":2005,"activeCount":102},[],{"intervention":2007,"totalTrials":120,"cells":2008},"Intravenous Iron sucrose",{"EARLY_PHASE1":2009,"PHASE1":2011,"PHASE2":2013,"PHASE3":2015,"PHASE4":2030,"NA":2032},{"trials":2010,"activeCount":102},[],{"trials":2012,"activeCount":102},[],{"trials":2014,"activeCount":102},[],{"trials":2016,"activeCount":102},[2017],{"nctId":2018,"briefTitle":2019,"status":248,"phases":2020,"primaryCompletion":2021,"completion":2022,"start":2023,"enrollment":2024,"conditions":2025,"interventions":2028},"NCT01857011","Iron Supplementation for Acute Anemia After Postbariatric Abdominoplasty",[92],"2016-04","2016-06","2014-04",56,[2026,2027],"Anemia, Iron-Deficiency","Weight Loss",[2007,2029],"Oral Iron",{"trials":2031,"activeCount":102},[],{"trials":2033,"activeCount":102},[],{"intervention":2029,"totalTrials":120,"cells":2035},{"EARLY_PHASE1":2036,"PHASE1":2038,"PHASE2":2040,"PHASE3":2042,"PHASE4":2048,"NA":2050},{"trials":2037,"activeCount":102},[],{"trials":2039,"activeCount":102},[],{"trials":2041,"activeCount":102},[],{"trials":2043,"activeCount":102},[2044],{"nctId":2018,"briefTitle":2019,"status":248,"phases":2045,"primaryCompletion":2021,"completion":2022,"start":2023,"enrollment":2024,"conditions":2046,"interventions":2047},[92],[2026,2027],[2007,2029],{"trials":2049,"activeCount":102},[],{"trials":2051,"activeCount":102},[],{"intervention":2053,"totalTrials":120,"cells":2054},"Moxifloxacin and Dexamethasone combined",{"EARLY_PHASE1":2055,"PHASE1":2057,"PHASE2":2059,"PHASE3":2061,"PHASE4":2075,"NA":2077},{"trials":2056,"activeCount":102},[],{"trials":2058,"activeCount":102},[],{"trials":2060,"activeCount":102},[],{"trials":2062,"activeCount":102},[2063],{"nctId":2064,"briefTitle":2065,"status":248,"phases":2066,"primaryCompletion":1193,"completion":223,"start":2067,"enrollment":1310,"conditions":2068,"interventions":2072},"NCT00732446","Safety\u002FEfficacy of Antibiotic Steroid Combination in Treatment of Blepharitis and\u002For Keratitis and\u002For Conjunctivitis",[92],"2008-08",[2069,2070,2071],"Blepharitis","Conjunctivitis","Keratitis",[2053,2073,2074],"Moxifloxacin","Dexamethasone",{"trials":2076,"activeCount":102},[],{"trials":2078,"activeCount":102},[],{"intervention":2073,"totalTrials":120,"cells":2080},{"EARLY_PHASE1":2081,"PHASE1":2083,"PHASE2":2085,"PHASE3":2087,"PHASE4":2093,"NA":2095},{"trials":2082,"activeCount":102},[],{"trials":2084,"activeCount":102},[],{"trials":2086,"activeCount":102},[],{"trials":2088,"activeCount":102},[2089],{"nctId":2064,"briefTitle":2065,"status":248,"phases":2090,"primaryCompletion":1193,"completion":223,"start":2067,"enrollment":1310,"conditions":2091,"interventions":2092},[92],[2069,2070,2071],[2053,2073,2074],{"trials":2094,"activeCount":102},[],{"trials":2096,"activeCount":102},[],{"intervention":2074,"totalTrials":120,"cells":2098},{"EARLY_PHASE1":2099,"PHASE1":2101,"PHASE2":2103,"PHASE3":2105,"PHASE4":2111,"NA":2113},{"trials":2100,"activeCount":102},[],{"trials":2102,"activeCount":102},[],{"trials":2104,"activeCount":102},[],{"trials":2106,"activeCount":102},[2107],{"nctId":2064,"briefTitle":2065,"status":248,"phases":2108,"primaryCompletion":1193,"completion":223,"start":2067,"enrollment":1310,"conditions":2109,"interventions":2110},[92],[2069,2070,2071],[2053,2073,2074],{"trials":2112,"activeCount":102},[],{"trials":2114,"activeCount":102},[],{"intervention":2116,"totalTrials":120,"cells":2117},"Gabapentine",{"EARLY_PHASE1":2118,"PHASE1":2120,"PHASE2":2122,"PHASE3":2124,"PHASE4":2134,"NA":2136},{"trials":2119,"activeCount":102},[],{"trials":2121,"activeCount":102},[],{"trials":2123,"activeCount":102},[],{"trials":2125,"activeCount":102},[2126],{"nctId":2127,"briefTitle":2128,"status":248,"phases":2129,"primaryCompletion":1266,"completion":1904,"start":2130,"enrollment":149,"conditions":2131,"interventions":2133},"NCT01632215","Preoperative Gabapentine for Carpal Tunnel",[92],"2010-03",[2132],"Carpal Tunnel Syndrome",[2116],{"trials":2135,"activeCount":102},[],{"trials":2137,"activeCount":102},[],{"intervention":2139,"totalTrials":120,"cells":2140},"Eutectic mixture",{"EARLY_PHASE1":2141,"PHASE1":2143,"PHASE2":2145,"PHASE3":2147,"PHASE4":2161,"NA":2163},{"trials":2142,"activeCount":102},[],{"trials":2144,"activeCount":102},[],{"trials":2146,"activeCount":102},[],{"trials":2148,"activeCount":102},[2149],{"nctId":2150,"briefTitle":2151,"status":221,"phases":2152,"primaryCompletion":2153,"completion":2154,"start":2155,"enrollment":2156,"conditions":2157,"interventions":2159},"NCT00932542","Eutectic Mixture for Hemorrhoidectomy Postoperative",[91,92],"2011-02","2012-11","2010-04",144,[2158],"Hemorrhoidectomy",[2139,2160],"lidocaine 2,5%; prilocaine 2,5%",{"trials":2162,"activeCount":102},[],{"trials":2164,"activeCount":102},[],{"intervention":2160,"totalTrials":120,"cells":2166},{"EARLY_PHASE1":2167,"PHASE1":2169,"PHASE2":2171,"PHASE3":2173,"PHASE4":2179,"NA":2181},{"trials":2168,"activeCount":102},[],{"trials":2170,"activeCount":102},[],{"trials":2172,"activeCount":102},[],{"trials":2174,"activeCount":102},[2175],{"nctId":2150,"briefTitle":2151,"status":221,"phases":2176,"primaryCompletion":2153,"completion":2154,"start":2155,"enrollment":2156,"conditions":2177,"interventions":2178},[91,92],[2158],[2139,2160],{"trials":2180,"activeCount":102},[],{"trials":2182,"activeCount":102},[],{"intervention":2184,"totalTrials":120,"cells":2185},"Triamcinolone + Nepafenac",{"EARLY_PHASE1":2186,"PHASE1":2188,"PHASE2":2190,"PHASE3":2192,"PHASE4":2203,"NA":2205},{"trials":2187,"activeCount":102},[],{"trials":2189,"activeCount":102},[],{"trials":2191,"activeCount":102},[],{"trials":2193,"activeCount":102},[2194],{"nctId":2195,"briefTitle":2196,"status":248,"phases":2197,"primaryCompletion":2067,"completion":2198,"start":2199,"enrollment":149,"conditions":2200,"interventions":2201},"NCT00780780","Efficacy Study of Triamcinolone Associated With Nepafenac for Treatment of Diabetic Macular Edema",[92],"2012-10","2007-07",[1090],[2184,2202],"triamcinolone intravitreal",{"trials":2204,"activeCount":102},[],{"trials":2206,"activeCount":102},[],{"intervention":2202,"totalTrials":120,"cells":2208},{"EARLY_PHASE1":2209,"PHASE1":2211,"PHASE2":2213,"PHASE3":2215,"PHASE4":2221,"NA":2223},{"trials":2210,"activeCount":102},[],{"trials":2212,"activeCount":102},[],{"trials":2214,"activeCount":102},[],{"trials":2216,"activeCount":102},[2217],{"nctId":2195,"briefTitle":2196,"status":248,"phases":2218,"primaryCompletion":2067,"completion":2198,"start":2199,"enrollment":149,"conditions":2219,"interventions":2220},[92],[1090],[2184,2202],{"trials":2222,"activeCount":102},[],{"trials":2224,"activeCount":102},[],{"intervention":2226,"totalTrials":120,"cells":2227},"Aripiprazole",{"EARLY_PHASE1":2228,"PHASE1":2230,"PHASE2":2232,"PHASE3":2234,"PHASE4":2243,"NA":2245},{"trials":2229,"activeCount":102},[],{"trials":2231,"activeCount":102},[],{"trials":2233,"activeCount":102},[],{"trials":2235,"activeCount":102},[2236],{"nctId":2237,"briefTitle":2238,"status":248,"phases":2239,"completion":1043,"start":2240,"enrollment":149,"conditions":2241,"interventions":2242},"NCT00440713","Aripiprazole in the Treatment of Post-Traumatic Stress Disorder Symptoms",[92],"2004-01",[715],[2226],{"trials":2244,"activeCount":102},[],{"trials":2246,"activeCount":102},[],{"intervention":2248,"totalTrials":120,"cells":2249},"Pilocarpine Hydrochloride",{"EARLY_PHASE1":2250,"PHASE1":2252,"PHASE2":2254,"PHASE3":2256,"PHASE4":2268,"NA":2270},{"trials":2251,"activeCount":102},[],{"trials":2253,"activeCount":102},[],{"trials":2255,"activeCount":102},[],{"trials":2257,"activeCount":102},[2258],{"nctId":2259,"briefTitle":2260,"status":248,"phases":2261,"primaryCompletion":2262,"completion":2262,"start":2263,"enrollment":2264,"conditions":2265,"interventions":2267},"NCT04470479","Oral Pilocarpine in the Treatment of the Dry Eye of Patients With Sjogrens Syndrome",[92],"2006-04-01","2005-03-01",32,[2266],"Dry Eye",[2248],{"trials":2269,"activeCount":102},[],{"trials":2271,"activeCount":102},[],{"intervention":2273,"totalTrials":120,"cells":2274},"Lactulone",{"EARLY_PHASE1":2275,"PHASE1":2277,"PHASE2":2279,"PHASE3":2281,"PHASE4":2292,"NA":2294},{"trials":2276,"activeCount":102},[],{"trials":2278,"activeCount":102},[],{"trials":2280,"activeCount":102},[],{"trials":2282,"activeCount":102},[2283],{"nctId":2284,"briefTitle":2285,"status":248,"phases":2286,"primaryCompletion":2287,"start":1652,"enrollment":2288,"conditions":2289,"interventions":2291},"NCT01607060","Impact of Laxative Therapy With Lactulose in the Evolution of Organ Dysfunction in Critically Ill Patients.",[92],"2012-04",88,[2290],"Constipation",[2273],{"trials":2293,"activeCount":102},[],{"trials":2295,"activeCount":102},[],{"intervention":2297,"totalTrials":120,"cells":2298},"Cortisone",{"EARLY_PHASE1":2299,"PHASE1":2301,"PHASE2":2303,"PHASE3":2305,"PHASE4":2314,"NA":2316},{"trials":2300,"activeCount":102},[],{"trials":2302,"activeCount":102},[],{"trials":2304,"activeCount":102},[],{"trials":2306,"activeCount":102},[2307],{"nctId":2308,"briefTitle":2309,"status":221,"phases":2310,"primaryCompletion":2287,"completion":2287,"start":685,"enrollment":210,"conditions":2311,"interventions":2313},"NCT01447160","Effectiveness of Facet Joint Infiltration in Low Back Pain",[92],[2312],"Low Back Pain",[2297],{"trials":2315,"activeCount":102},[],{"trials":2317,"activeCount":102},[],{"intervention":2319,"totalTrials":120,"cells":2320},"Drug treatment",{"EARLY_PHASE1":2321,"PHASE1":2323,"PHASE2":2325,"PHASE3":2327,"PHASE4":2337,"NA":2339},{"trials":2322,"activeCount":102},[],{"trials":2324,"activeCount":102},[],{"trials":2326,"activeCount":102},[],{"trials":2328,"activeCount":102},[2329],{"nctId":2330,"briefTitle":2331,"status":221,"phases":2332,"primaryCompletion":684,"completion":684,"start":1856,"enrollment":2333,"conditions":2334,"interventions":2336},"NCT01586663","Serial Night Time Position Splint on Systemic Sclerosis",[92],76,[2335],"Diffuse Systemic Sclerosis",[2319],{"trials":2338,"activeCount":102},[],{"trials":2340,"activeCount":102},[],{"intervention":2342,"totalTrials":120,"cells":2343},"Flaxseed oil",{"EARLY_PHASE1":2344,"PHASE1":2346,"PHASE2":2348,"PHASE3":2350,"PHASE4":2362,"NA":2364},{"trials":2345,"activeCount":102},[],{"trials":2347,"activeCount":102},[],{"trials":2349,"activeCount":102},[],{"trials":2351,"activeCount":102},[2352],{"nctId":2353,"briefTitle":2354,"status":248,"phases":2355,"primaryCompletion":2356,"completion":2356,"start":667,"enrollment":349,"conditions":2357,"interventions":2360},"NCT01391624","Study on the Possible Effects of Diet Supplementation With Essential Fatty Acids in Chocolate Craving Volunteers",[91,92],"2011-01",[2358,2359],"Addictive Behavior","Abstinence Syndrome",[2342,2361],"Paraffin + # 2 dye",{"trials":2363,"activeCount":102},[],{"trials":2365,"activeCount":102},[],{"intervention":2361,"totalTrials":120,"cells":2367},{"EARLY_PHASE1":2368,"PHASE1":2370,"PHASE2":2372,"PHASE3":2374,"PHASE4":2380,"NA":2382},{"trials":2369,"activeCount":102},[],{"trials":2371,"activeCount":102},[],{"trials":2373,"activeCount":102},[],{"trials":2375,"activeCount":102},[2376],{"nctId":2353,"briefTitle":2354,"status":248,"phases":2377,"primaryCompletion":2356,"completion":2356,"start":667,"enrollment":349,"conditions":2378,"interventions":2379},[91,92],[2358,2359],[2342,2361],{"trials":2381,"activeCount":102},[],{"trials":2383,"activeCount":102},[],{"intervention":2385,"totalTrials":120,"cells":2386},"H. pylori triple therapy",{"EARLY_PHASE1":2387,"PHASE1":2389,"PHASE2":2391,"PHASE3":2393,"PHASE4":2405,"NA":2407},{"trials":2388,"activeCount":102},[],{"trials":2390,"activeCount":102},[],{"trials":2392,"activeCount":102},[],{"trials":2394,"activeCount":102},[2395],{"nctId":2396,"briefTitle":2397,"status":248,"phases":2398,"primaryCompletion":2399,"completion":1904,"start":2400,"enrollment":1310,"conditions":2401,"interventions":2404},"NCT01730352","Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients",[91,92],"2011-05","2008-10",[2402,2403],"Immune Thrombocytopenic Purpura","Helicobacter Pylori Infection",[2385],{"trials":2406,"activeCount":102},[],{"trials":2408,"activeCount":102},[],{"intervention":2410,"totalTrials":120,"cells":2411},"Biperiden Lactate",{"EARLY_PHASE1":2412,"PHASE1":2414,"PHASE2":2416,"PHASE3":2418,"PHASE4":2430,"NA":2432},{"trials":2413,"activeCount":102},[],{"trials":2415,"activeCount":102},[],{"trials":2417,"activeCount":102},[],{"trials":2419,"activeCount":102},[2420],{"nctId":2421,"briefTitle":2422,"status":761,"phases":2423,"primaryCompletion":2424,"completion":2424,"start":2425,"enrollment":2426,"conditions":2427,"interventions":2429},"NCT01048138","Use of Biperiden for the Prevention of Post-traumatic Epilepsy",[92],"2022-12-02","2018-01-31",123,[2428],"Traumatic Brain Injury",[2410],{"trials":2431,"activeCount":102},[],{"trials":2433,"activeCount":102},[],{"intervention":2435,"totalTrials":120,"cells":2436},"Vildagliptin",{"EARLY_PHASE1":2437,"PHASE1":2439,"PHASE2":2441,"PHASE3":2443,"PHASE4":2456,"NA":2458},{"trials":2438,"activeCount":102},[],{"trials":2440,"activeCount":102},[],{"trials":2442,"activeCount":102},[],{"trials":2444,"activeCount":102},[2445],{"nctId":2446,"briefTitle":2447,"status":221,"phases":2448,"primaryCompletion":1087,"completion":785,"start":1088,"enrollment":2449,"conditions":2450,"interventions":2455},"NCT01559025","Evaluation of Vildagliptin (Galvus®) as add-on to Insulin in New-onset Type 1 Diabetes Mellitus",[92],44,[2451,2452,2453,2454],"Type 1 Diabetes","Insulin Dependent Diabetes","Juvenile Onset Diabetes Mellitus","Autoimmune Diabetes",[2435],{"trials":2457,"activeCount":102},[],{"trials":2459,"activeCount":102},[],{"intervention":2461,"totalTrials":120,"cells":2462},"Naltrexone",{"EARLY_PHASE1":2463,"PHASE1":2465,"PHASE2":2467,"PHASE3":2469,"PHASE4":2482,"NA":2484},{"trials":2464,"activeCount":102},[],{"trials":2466,"activeCount":102},[],{"trials":2468,"activeCount":102},[],{"trials":2470,"activeCount":102},[2471],{"nctId":2472,"briefTitle":2473,"status":248,"phases":2474,"primaryCompletion":1309,"completion":1309,"start":2475,"enrollment":2476,"conditions":2477,"interventions":2479},"NCT01211769","Effects of Omegas 3 and 6 on Alcohol Dependence",[92],"2006-02",80,[2478],"Alcohol Dependence",[2461,2480,2481],"PUFAs","Naltrexone + Placebo",{"trials":2483,"activeCount":102},[],{"trials":2485,"activeCount":102},[],{"intervention":2480,"totalTrials":120,"cells":2487},{"EARLY_PHASE1":2488,"PHASE1":2490,"PHASE2":2492,"PHASE3":2494,"PHASE4":2500,"NA":2502},{"trials":2489,"activeCount":102},[],{"trials":2491,"activeCount":102},[],{"trials":2493,"activeCount":102},[],{"trials":2495,"activeCount":102},[2496],{"nctId":2472,"briefTitle":2473,"status":248,"phases":2497,"primaryCompletion":1309,"completion":1309,"start":2475,"enrollment":2476,"conditions":2498,"interventions":2499},[92],[2478],[2461,2480,2481],{"trials":2501,"activeCount":102},[],{"trials":2503,"activeCount":102},[],{"intervention":2481,"totalTrials":120,"cells":2505},{"EARLY_PHASE1":2506,"PHASE1":2508,"PHASE2":2510,"PHASE3":2512,"PHASE4":2518,"NA":2520},{"trials":2507,"activeCount":102},[],{"trials":2509,"activeCount":102},[],{"trials":2511,"activeCount":102},[],{"trials":2513,"activeCount":102},[2514],{"nctId":2472,"briefTitle":2473,"status":248,"phases":2515,"primaryCompletion":1309,"completion":1309,"start":2475,"enrollment":2476,"conditions":2516,"interventions":2517},[92],[2478],[2461,2480,2481],{"trials":2519,"activeCount":102},[],{"trials":2521,"activeCount":102},[],{"intervention":2523,"totalTrials":120,"cells":2524},"Ramipril",{"EARLY_PHASE1":2525,"PHASE1":2527,"PHASE2":2529,"PHASE3":2531,"PHASE4":2543,"NA":2545},{"trials":2526,"activeCount":102},[],{"trials":2528,"activeCount":102},[],{"trials":2530,"activeCount":102},[],{"trials":2532,"activeCount":102},[2533],{"nctId":2534,"briefTitle":2535,"status":248,"phases":2536,"primaryCompletion":2537,"completion":644,"start":2538,"enrollment":2539,"conditions":2540,"interventions":2542},"NCT03979976","Ramipril, Endothelial Function and Endothelial Progenitor Cells in Patients With Systemic Lupus Erythematosus",[91,92],"2013-08","2011-03",37,[2541],"Systemic Lupus Erythematosus",[2523],{"trials":2544,"activeCount":102},[],{"trials":2546,"activeCount":102},[],{"intervention":2548,"totalTrials":120,"cells":2549},"Biperiden",{"EARLY_PHASE1":2550,"PHASE1":2552,"PHASE2":2554,"PHASE3":2556,"PHASE4":2567,"NA":2569},{"trials":2551,"activeCount":102},[],{"trials":2553,"activeCount":102},[],{"trials":2555,"activeCount":102},[],{"trials":2557,"activeCount":102},[2558],{"nctId":2559,"briefTitle":2560,"status":248,"phases":2561,"primaryCompletion":2562,"completion":2154,"start":2399,"enrollment":2563,"conditions":2564,"interventions":2566},"NCT01251393","Cocaine\u002FCrack and Reduction of Compulsion With Biperiden",[92],"2011-12",111,[2565],"Cocaine Dependence",[2548],{"trials":2568,"activeCount":102},[],{"trials":2570,"activeCount":102},[],{"intervention":2572,"totalTrials":98,"cells":2573},"Clonidine",{"EARLY_PHASE1":2574,"PHASE1":2576,"PHASE2":2578,"PHASE3":2597,"PHASE4":2599,"NA":2601},{"trials":2575,"activeCount":102},[],{"trials":2577,"activeCount":102},[],{"trials":2579,"activeCount":102},[2580,2589],{"nctId":2581,"briefTitle":2582,"status":248,"phases":2583,"primaryCompletion":566,"completion":1904,"start":2584,"enrollment":2585,"conditions":2586,"interventions":2588},"NCT01597427","Reduction of Pulmonary Artery Pressure in Patients Subjected to Cardiac Surgery",[91],"2009-03",29,[2587],"Anesthesia",[2572],{"nctId":2590,"briefTitle":2591,"status":221,"phases":2592,"primaryCompletion":250,"completion":684,"start":2593,"enrollment":149,"conditions":2594,"interventions":2596},"NCT01677351","Assessment of the Effect of Clonidine for Cataract Surgery",[91],"2011-07",[24,2595],"Arrythmia",[2572],{"trials":2598,"activeCount":102},[],{"trials":2600,"activeCount":102},[],{"trials":2602,"activeCount":102},[],{"intervention":2604,"totalTrials":120,"cells":2605},"Metaraminol",{"EARLY_PHASE1":2606,"PHASE1":2608,"PHASE2":2610,"PHASE3":2620,"PHASE4":2622,"NA":2624},{"trials":2607,"activeCount":102},[],{"trials":2609,"activeCount":102},[],{"trials":2611,"activeCount":102},[2612],{"nctId":2613,"briefTitle":2614,"status":248,"phases":2615,"primaryCompletion":667,"completion":667,"start":224,"enrollment":2616,"conditions":2617,"interventions":2619},"NCT01108874","Up-Down Determination of the ED90 of Metaraminol to Treat Hypotension During Cesarean Section",[91],48,[2618],"Hypotension",[2604],{"trials":2621,"activeCount":102},[],{"trials":2623,"activeCount":102},[],{"trials":2625,"activeCount":102},[],{"intervention":604,"totalTrials":120,"cells":2627},{"EARLY_PHASE1":2628,"PHASE1":2630,"PHASE2":2632,"PHASE3":2638,"PHASE4":2640,"NA":2642},{"trials":2629,"activeCount":102},[],{"trials":2631,"activeCount":102},[],{"trials":2633,"activeCount":102},[2634],{"nctId":594,"briefTitle":595,"status":248,"phases":2635,"primaryCompletion":597,"completion":598,"start":599,"enrollment":600,"conditions":2636,"interventions":2637},[91],[602],[604,230],{"trials":2639,"activeCount":102},[],{"trials":2641,"activeCount":102},[],{"trials":2643,"activeCount":102},[],{"intervention":2645,"totalTrials":120,"cells":2646},"Dobutamine",{"EARLY_PHASE1":2647,"PHASE1":2649,"PHASE2":2651,"PHASE3":2665,"PHASE4":2667,"NA":2669},{"trials":2648,"activeCount":102},[],{"trials":2650,"activeCount":102},[],{"trials":2652,"activeCount":102},[2653],{"nctId":2654,"briefTitle":2655,"status":221,"phases":2656,"primaryCompletion":2657,"completion":2658,"start":2659,"enrollment":298,"conditions":2660,"interventions":2664},"NCT05953142","Use of Dobutamine in Patients With Sepsis and Maintained Hypoperfusion After Initial Volemic Resuscitation.",[91],"2025-12-31","2026-03-31","2024-02-01",[2661,2662,2663],"Sepsis","Hypoperfusion","Hyperlactatemia",[2645],{"trials":2666,"activeCount":102},[],{"trials":2668,"activeCount":102},[],{"trials":2670,"activeCount":102},[],{"intervention":2672,"totalTrials":120,"cells":2673},"intraarticular",{"EARLY_PHASE1":2674,"PHASE1":2676,"PHASE2":2678,"PHASE3":2686,"PHASE4":2688,"NA":2690},{"trials":2675,"activeCount":102},[],{"trials":2677,"activeCount":102},[],{"trials":2679,"activeCount":102},[2680],{"nctId":2681,"briefTitle":2682,"status":248,"phases":2683,"completion":631,"start":1837,"enrollment":210,"conditions":2684,"interventions":2685},"NCT00506896","Monoarticular Corticosteroid Injection Versus Systemic Administration in the Treatment of Rheumatoid Arthritis Patients",[91],[21],[2672],{"trials":2687,"activeCount":102},[],{"trials":2689,"activeCount":102},[],{"trials":2691,"activeCount":102},[],{"intervention":2693,"totalTrials":120,"cells":2694},"triamcinolone acetonide",{"EARLY_PHASE1":2695,"PHASE1":2697,"PHASE2":2699,"PHASE3":2709,"PHASE4":2711,"NA":2713},{"trials":2696,"activeCount":102},[],{"trials":2698,"activeCount":102},[],{"trials":2700,"activeCount":102},[2701],{"nctId":2702,"briefTitle":2703,"status":221,"phases":2704,"primaryCompletion":2705,"completion":2067,"start":2706,"enrollment":686,"conditions":2707,"interventions":2708},"NCT00407849","Intravitreal Triamcinolone Acetonide for Treatment of Refractory Diffuse Diabetic Macular Edema",[90,91],"2007-12","2006-10",[1654],[2693],{"trials":2710,"activeCount":102},[],{"trials":2712,"activeCount":102},[],{"trials":2714,"activeCount":102},[],{"intervention":2716,"totalTrials":120,"cells":2717},"bupivacaine 0.5%",{"EARLY_PHASE1":2718,"PHASE1":2720,"PHASE2":2722,"PHASE3":2731,"PHASE4":2733,"NA":2735},{"trials":2719,"activeCount":102},[],{"trials":2721,"activeCount":102},[],{"trials":2723,"activeCount":102},[2724],{"nctId":2725,"briefTitle":2726,"status":248,"phases":2727,"primaryCompletion":1308,"completion":1308,"start":2728,"enrollment":1196,"conditions":2729,"interventions":2730},"NCT01244932","Minimum Effective Volume of Local Anesthetic Using Ultrasound for Brachial Plexus Block",[91],"2009-09",[2587],[2716],{"trials":2732,"activeCount":102},[],{"trials":2734,"activeCount":102},[],{"trials":2736,"activeCount":102},[],{"intervention":2738,"totalTrials":120,"cells":2739},"Oxybutynin 5 mg pills",{"EARLY_PHASE1":2740,"PHASE1":2742,"PHASE2":2744,"PHASE3":2754,"PHASE4":2756,"NA":2758},{"trials":2741,"activeCount":102},[],{"trials":2743,"activeCount":102},[],{"trials":2745,"activeCount":102},[2746],{"nctId":2747,"briefTitle":2748,"status":248,"phases":2749,"primaryCompletion":1848,"completion":2750,"start":2130,"enrollment":2264,"conditions":2751,"interventions":2753},"NCT01328015","A Study to Compare Oxybutynin to a Placebo in Women and the Effect on Plantar Hyperhidrosis",[91],"2010-06",[2752],"Hyperhidrosis",[2738],{"trials":2755,"activeCount":102},[],{"trials":2757,"activeCount":102},[],{"trials":2759,"activeCount":102},[],{"intervention":2761,"totalTrials":120,"cells":2762},"Bupivacaine 0,375%",{"EARLY_PHASE1":2763,"PHASE1":2765,"PHASE2":2767,"PHASE3":2776,"PHASE4":2778,"NA":2780},{"trials":2764,"activeCount":102},[],{"trials":2766,"activeCount":102},[],{"trials":2768,"activeCount":102},[2769],{"nctId":2770,"briefTitle":2771,"status":221,"phases":2772,"primaryCompletion":565,"completion":644,"start":1264,"enrollment":1196,"conditions":2773,"interventions":2775},"NCT01667315","Minimum Effective Volume of 0.375% Bupivacaine in Interscalene Brachial Plexus Block",[91],[2774],"Shoulder Surgery",[2761],{"trials":2777,"activeCount":102},[],{"trials":2779,"activeCount":102},[],{"trials":2781,"activeCount":102},[],{"intervention":2783,"totalTrials":120,"cells":2784},"Clomiphene citrate",{"EARLY_PHASE1":2785,"PHASE1":2787,"PHASE2":2789,"PHASE3":2802,"PHASE4":2804,"NA":2806},{"trials":2786,"activeCount":102},[],{"trials":2788,"activeCount":102},[],{"trials":2790,"activeCount":102},[2791],{"nctId":2792,"briefTitle":2793,"status":248,"phases":2794,"primaryCompletion":2795,"completion":2795,"start":2796,"enrollment":2797,"conditions":2798,"interventions":2801},"NCT00697814","Clomiphene in Males With Prolactinomas and Persistent Hypogonadism",[91],"2005-06","2004-06",15,[2799,2800],"Hypogonadotropic Hypogonadism","Prolactinoma",[2783],{"trials":2803,"activeCount":102},[],{"trials":2805,"activeCount":102},[],{"trials":2807,"activeCount":102},[],{"intervention":2809,"totalTrials":120,"cells":2810},"Pregabalin",{"EARLY_PHASE1":2811,"PHASE1":2813,"PHASE2":2815,"PHASE3":2823,"PHASE4":2825,"NA":2827},{"trials":2812,"activeCount":102},[],{"trials":2814,"activeCount":102},[],{"trials":2816,"activeCount":102},[2817],{"nctId":2818,"briefTitle":2819,"status":248,"phases":2820,"primaryCompletion":2562,"completion":2562,"start":2538,"enrollment":149,"conditions":2821,"interventions":2822},"NCT01529190","Pregabalin on Interleukin-6 Levels in Living Donor Kidney",[91],[24],[2809],{"trials":2824,"activeCount":102},[],{"trials":2826,"activeCount":102},[],{"trials":2828,"activeCount":102},[],{"intervention":2830,"totalTrials":120,"cells":2831},"bevacizumab",{"EARLY_PHASE1":2832,"PHASE1":2834,"PHASE2":2836,"PHASE3":2847,"PHASE4":2849,"NA":2851},{"trials":2833,"activeCount":102},[],{"trials":2835,"activeCount":102},[],{"trials":2837,"activeCount":102},[2838],{"nctId":2839,"briefTitle":2840,"status":221,"phases":2841,"primaryCompletion":2842,"start":1195,"enrollment":686,"conditions":2843,"interventions":2845},"NCT00684853","Intravitreal Bevacizumab Combined With PDT Versus Bevacizumab to Treat Exudative AMD",[91],"2008-05",[2844],"Macular Degeneration",[2830,2846],"vetaporfin",{"trials":2848,"activeCount":102},[],{"trials":2850,"activeCount":102},[],{"trials":2852,"activeCount":102},[],{"intervention":2846,"totalTrials":120,"cells":2854},{"EARLY_PHASE1":2855,"PHASE1":2857,"PHASE2":2859,"PHASE3":2865,"PHASE4":2867,"NA":2869},{"trials":2856,"activeCount":102},[],{"trials":2858,"activeCount":102},[],{"trials":2860,"activeCount":102},[2861],{"nctId":2839,"briefTitle":2840,"status":221,"phases":2862,"primaryCompletion":2842,"start":1195,"enrollment":686,"conditions":2863,"interventions":2864},[91],[2844],[2830,2846],{"trials":2866,"activeCount":102},[],{"trials":2868,"activeCount":102},[],{"trials":2870,"activeCount":102},[],{"intervention":674,"totalTrials":120,"cells":2872},{"EARLY_PHASE1":2873,"PHASE1":2875,"PHASE2":2877,"PHASE3":2883,"PHASE4":2885,"NA":2887},{"trials":2874,"activeCount":102},[],{"trials":2876,"activeCount":102},[],{"trials":2878,"activeCount":102},[2879],{"nctId":663,"briefTitle":664,"status":221,"phases":2880,"primaryCompletion":666,"completion":667,"start":668,"enrollment":669,"conditions":2881,"interventions":2882},[91],[671,672],[654,674],{"trials":2884,"activeCount":102},[],{"trials":2886,"activeCount":102},[],{"trials":2888,"activeCount":102},[],{"intervention":2890,"totalTrials":120,"cells":2891},"Methylene Blue",{"EARLY_PHASE1":2892,"PHASE1":2894,"PHASE2":2896,"PHASE3":2911,"PHASE4":2913,"NA":2915},{"trials":2893,"activeCount":102},[],{"trials":2895,"activeCount":102},[],{"trials":2897,"activeCount":102},[2898],{"nctId":2899,"briefTitle":2900,"status":248,"phases":2901,"primaryCompletion":2902,"completion":2902,"start":2903,"enrollment":2904,"conditions":2905,"interventions":2910},"NCT05092165","Methylene Blue for the Prevention of Hypotension During Hemodialysis",[91],"2025-12-16","2021-10-21",261,[2906,2907,2908,2909],"Acute Kidney Injury","Shock","Intradialytic Hypotension","Intradialytic Hypertension in Hemodialysis Patients",[2890],{"trials":2912,"activeCount":102},[],{"trials":2914,"activeCount":102},[],{"trials":2916,"activeCount":102},[],{"intervention":2918,"totalTrials":120,"cells":2919},"balanced crystalloid solution",{"EARLY_PHASE1":2920,"PHASE1":2922,"PHASE2":2924,"PHASE3":2938,"PHASE4":2940,"NA":2942},{"trials":2921,"activeCount":102},[],{"trials":2923,"activeCount":102},[],{"trials":2925,"activeCount":102},[2926],{"nctId":2927,"briefTitle":2928,"status":248,"phases":2929,"primaryCompletion":2930,"completion":2931,"start":2932,"enrollment":2933,"conditions":2934,"interventions":2936},"NCT02707549","Fluid Therapy During Brain Tumor Resection in Children",[91],"2016-12","2017-06","2015-08",53,[2935],"Brain Neoplasms",[2918,2937],"0.9% sodium chloride",{"trials":2939,"activeCount":102},[],{"trials":2941,"activeCount":102},[],{"trials":2943,"activeCount":102},[],{"intervention":2937,"totalTrials":120,"cells":2945},{"EARLY_PHASE1":2946,"PHASE1":2948,"PHASE2":2950,"PHASE3":2956,"PHASE4":2958,"NA":2960},{"trials":2947,"activeCount":102},[],{"trials":2949,"activeCount":102},[],{"trials":2951,"activeCount":102},[2952],{"nctId":2927,"briefTitle":2928,"status":248,"phases":2953,"primaryCompletion":2930,"completion":2931,"start":2932,"enrollment":2933,"conditions":2954,"interventions":2955},[91],[2935],[2918,2937],{"trials":2957,"activeCount":102},[],{"trials":2959,"activeCount":102},[],{"trials":2961,"activeCount":102},[],{"intervention":2963,"totalTrials":120,"cells":2964},"Aspirin",{"EARLY_PHASE1":2965,"PHASE1":2967,"PHASE2":2969,"PHASE3":2981,"PHASE4":2983,"NA":2985},{"trials":2966,"activeCount":102},[],{"trials":2968,"activeCount":102},[],{"trials":2970,"activeCount":102},[2971],{"nctId":2972,"briefTitle":2973,"status":761,"phases":2974,"primaryCompletion":2975,"completion":2976,"start":2977,"enrollment":2978,"conditions":2979,"interventions":2980},"NCT01784159","ASpirin for Patients With SEPsis and SeptIc Shock",[91],"2022-12-15","2023-01-05","2019-03-27",167,[2661],[2963],{"trials":2982,"activeCount":102},[],{"trials":2984,"activeCount":102},[],{"trials":2986,"activeCount":102},[],{"intervention":2988,"totalTrials":120,"cells":2989},"Tea Tree Oil",{"EARLY_PHASE1":2990,"PHASE1":2992,"PHASE2":2994,"PHASE3":3004,"PHASE4":3006,"NA":3008},{"trials":2991,"activeCount":102},[],{"trials":2993,"activeCount":102},[],{"trials":2995,"activeCount":102},[2996],{"nctId":2997,"briefTitle":2998,"status":248,"phases":2999,"primaryCompletion":1857,"completion":224,"start":3000,"enrollment":3001,"conditions":3002,"interventions":3003},"NCT01073150","Tea Tree Oil in the Treatment of Chronic Blepharitis",[91],"2009-04",34,[2069],[2988],{"trials":3005,"activeCount":102},[],{"trials":3007,"activeCount":102},[],{"trials":3009,"activeCount":102},[],{"intervention":3011,"totalTrials":120,"cells":3012},"oral isotretinoin and Mexoryl SX \u002F XL",{"EARLY_PHASE1":3013,"PHASE1":3015,"PHASE2":3017,"PHASE3":3028,"PHASE4":3030,"NA":3032},{"trials":3014,"activeCount":102},[],{"trials":3016,"activeCount":102},[],{"trials":3018,"activeCount":102},[3019],{"nctId":3020,"briefTitle":3021,"status":248,"phases":3022,"primaryCompletion":3023,"completion":1309,"start":2199,"enrollment":2264,"conditions":3024,"interventions":3026},"NCT00701740","Oral Isotretinoin for Photoaging: Results of a Randomized Controlled Phase II Trial",[91],"2008-01",[672,3025],"Epidermal p53 Expression",[3011,3027],"Mexoryl XL \u002F SX",{"trials":3029,"activeCount":102},[],{"trials":3031,"activeCount":102},[],{"trials":3033,"activeCount":102},[],{"intervention":3027,"totalTrials":120,"cells":3035},{"EARLY_PHASE1":3036,"PHASE1":3038,"PHASE2":3040,"PHASE3":3046,"PHASE4":3048,"NA":3050},{"trials":3037,"activeCount":102},[],{"trials":3039,"activeCount":102},[],{"trials":3041,"activeCount":102},[3042],{"nctId":3020,"briefTitle":3021,"status":248,"phases":3043,"primaryCompletion":3023,"completion":1309,"start":2199,"enrollment":2264,"conditions":3044,"interventions":3045},[91],[672,3025],[3011,3027],{"trials":3047,"activeCount":102},[],{"trials":3049,"activeCount":102},[],{"trials":3051,"activeCount":102},[],{"intervention":3053,"totalTrials":120,"cells":3054},"Cholecalciferol",{"EARLY_PHASE1":3055,"PHASE1":3057,"PHASE2":3059,"PHASE3":3070,"PHASE4":3072,"NA":3074},{"trials":3056,"activeCount":102},[],{"trials":3058,"activeCount":102},[],{"trials":3060,"activeCount":102},[3061],{"nctId":3062,"briefTitle":3063,"status":248,"phases":3064,"primaryCompletion":3065,"completion":3065,"start":683,"enrollment":3066,"conditions":3067,"interventions":3069},"NCT01974245","Supplementation With Cholecalciferol in Dialysis Patients",[91],"2014-07",55,[3068],"Chronic Kidney Disease",[3053],{"trials":3071,"activeCount":102},[],{"trials":3073,"activeCount":102},[],{"trials":3075,"activeCount":102},[],{"intervention":3077,"totalTrials":120,"cells":3078},"Cephalexin",{"EARLY_PHASE1":3079,"PHASE1":3081,"PHASE2":3083,"PHASE3":3094,"PHASE4":3096,"NA":3098},{"trials":3080,"activeCount":102},[],{"trials":3082,"activeCount":102},[],{"trials":3084,"activeCount":102},[3085],{"nctId":3086,"briefTitle":3087,"status":248,"phases":3088,"primaryCompletion":1583,"completion":1446,"start":3089,"enrollment":3090,"conditions":3091,"interventions":3093},"NCT02569866","Antibiotics After Breast Reduction:Clinical Trial With Randomization",[91],"2014-11",124,[3092],"Surgical Site Infection",[3077],{"trials":3095,"activeCount":102},[],{"trials":3097,"activeCount":102},[],{"trials":3099,"activeCount":102},[],{"intervention":3101,"totalTrials":120,"cells":3102},"0.12% Chlorhexidine Digluconate",{"EARLY_PHASE1":3103,"PHASE1":3105,"PHASE2":3116,"PHASE3":3118,"PHASE4":3120,"NA":3122},{"trials":3104,"activeCount":102},[],{"trials":3106,"activeCount":102},[3107],{"nctId":3108,"briefTitle":3109,"status":248,"phases":3110,"primaryCompletion":3111,"completion":1309,"start":2795,"enrollment":3112,"conditions":3113,"interventions":3115},"NCT01083407","Oral Care Interventions and Ventilator Associated Pneumonia in Critically Ill Children",[90],"2006-06",146,[3114],"Ventilator Associated Pneumonia",[3101],{"trials":3117,"activeCount":102},[],{"trials":3119,"activeCount":102},[],{"trials":3121,"activeCount":102},[],{"trials":3123,"activeCount":102},[],{"intervention":3125,"totalTrials":3126,"cells":3127},"Lidocaine",4,{"EARLY_PHASE1":3128,"PHASE1":3130,"PHASE2":3139,"PHASE3":3141,"PHASE4":3150,"NA":3152},{"trials":3129,"activeCount":102},[],{"trials":3131,"activeCount":102},[3132],{"nctId":3133,"briefTitle":3134,"status":248,"phases":3135,"primaryCompletion":2199,"completion":1652,"start":3136,"enrollment":349,"conditions":3137,"interventions":3138},"NCT00991848","Lidocaine on Manifestations of Fibromyalgia",[90],"2005-01",[18,35],[3125],{"trials":3140,"activeCount":102},[],{"trials":3142,"activeCount":102},[3143],{"nctId":3144,"briefTitle":3145,"status":221,"phases":3146,"primaryCompletion":683,"completion":684,"start":1856,"enrollment":149,"conditions":3147,"interventions":3148},"NCT01391598","Lidocaine on Pain Relief and IL and Substance P in Fibromyalgia",[92],[18],[3125,3149],"lidocaine",{"trials":3151,"activeCount":102},[],{"trials":3153,"activeCount":102},[3154,3161],{"nctId":3155,"briefTitle":3156,"status":248,"phases":3157,"primaryCompletion":2400,"completion":1193,"start":2842,"enrollment":149,"conditions":3158,"interventions":3160},"NCT00965796","Intraoperative Intravenous Lidocaine",[94],[3159],"Pain Intensity",[3125],{"nctId":3162,"briefTitle":3163,"status":248,"phases":3164,"primaryCompletion":3165,"completion":2705,"start":3166,"enrollment":349,"conditions":3167,"interventions":3168},"NCT00986505","Intravenous Lidocaine for Fibromyalgia",[94],"2007-10","2005-02",[18],[3125],{"intervention":231,"totalTrials":1824,"cells":3170},{"EARLY_PHASE1":3171,"PHASE1":3173,"PHASE2":3175,"PHASE3":3177,"PHASE4":3183,"NA":3189},{"trials":3172,"activeCount":102},[],{"trials":3174,"activeCount":102},[],{"trials":3176,"activeCount":102},[],{"trials":3178,"activeCount":102},[3179],{"nctId":627,"briefTitle":628,"status":248,"phases":3180,"primaryCompletion":630,"completion":630,"start":631,"enrollment":632,"conditions":3181,"interventions":3182},[92],[24,634,635],[637,616],{"trials":3184,"activeCount":102},[3185],{"nctId":219,"briefTitle":220,"status":221,"phases":3186,"primaryCompletion":223,"completion":224,"start":225,"enrollment":226,"conditions":3187,"interventions":3188},[93],[228],[230,194,231],{"trials":3190,"activeCount":102},[3191],{"nctId":3192,"briefTitle":3193,"status":248,"phases":3194,"primaryCompletion":2795,"completion":1041,"start":3195,"enrollment":349,"conditions":3196,"interventions":3198},"NCT00635986","Analgesic Effect and Plasma Concentration of Epidural Versus Intravenous Fentanyl",[94],"2004-05",[3197],"Fentanyl Analgesia",[231],{"intervention":256,"totalTrials":1824,"cells":3200},{"EARLY_PHASE1":3201,"PHASE1":3203,"PHASE2":3205,"PHASE3":3207,"PHASE4":3213,"NA":3226},{"trials":3202,"activeCount":102},[],{"trials":3204,"activeCount":102},[],{"trials":3206,"activeCount":102},[],{"trials":3208,"activeCount":102},[3209],{"nctId":246,"briefTitle":247,"status":248,"phases":3210,"primaryCompletion":250,"completion":250,"start":251,"enrollment":210,"conditions":3211,"interventions":3212},[92],[24,253,254],[235,256],{"trials":3214,"activeCount":102},[3215],{"nctId":3216,"briefTitle":3217,"status":221,"phases":3218,"primaryCompletion":3219,"completion":2930,"start":3220,"enrollment":3221,"conditions":3222,"interventions":3223},"NCT02829281","Intra-articular Botox Type A Versus Corticosteroids in Knee Osteoarthritis",[93],"2016-10","2016-07",105,[26],[3224,3225,256],"Botulinum Toxin Type A","Triamcinolone hexacetonide",{"trials":3227,"activeCount":102},[3228],{"nctId":3229,"briefTitle":3230,"status":248,"phases":3231,"primaryCompletion":668,"completion":666,"start":3232,"enrollment":3233,"conditions":3234,"interventions":3236},"NCT01612013","Intravenous High Dose NAC and Sodium Bicarbonate for the Prevention of Contrast-induced Acute Injury",[94],"2005-05",500,[3235],"Acute Renal Failure",[3237,3238,3239,256,3240,3239],"Sodium bicarbonate plus saline","Intravenous NAC plus saline","NAC plus sodium bicarbonate plus saline","NAC plus saline",{"intervention":3242,"totalTrials":1824,"cells":3243},"Bupivacaine",{"EARLY_PHASE1":3244,"PHASE1":3246,"PHASE2":3248,"PHASE3":3250,"PHASE4":3252,"NA":3254},{"trials":3245,"activeCount":102},[],{"trials":3247,"activeCount":102},[],{"trials":3249,"activeCount":102},[],{"trials":3251,"activeCount":102},[],{"trials":3253,"activeCount":102},[],{"trials":3255,"activeCount":102},[3256,3265,3274],{"nctId":3257,"briefTitle":3258,"status":248,"phases":3259,"primaryCompletion":3260,"completion":3260,"start":565,"enrollment":149,"conditions":3261,"interventions":3263},"NCT01927874","Subarachnoid or Infiltration for Hemorrhoidectomy",[94],"2015-11",[3262],"Hemorrhoid",[3242,3264],"10 mg of hyperbaric 0.5% bupivacaine",{"nctId":3266,"briefTitle":3267,"status":248,"phases":3268,"primaryCompletion":3269,"completion":3270,"start":667,"enrollment":3271,"conditions":3272,"interventions":3273},"NCT01838928","Minimum Effective Concentration of Bupivacaine in Ultrasound-guided Axillary Brachial Plexus Block",[94],"2010-12","2012-06",46,[24],[3242],{"nctId":3275,"briefTitle":3276,"status":221,"phases":3277,"primaryCompletion":3278,"completion":3279,"start":3280,"enrollment":149,"conditions":3281,"interventions":3285},"NCT03488888","PEC Block II in Mammoplasty Surgeries",[94],"2018-12-01","2019-01-01","2017-11-03",[3282,3283,635,3284],"Mammaplasty","Anesthesia, Conduction","Analgesia, Patient-Controlled",[3286,3242],"Normal Saline 0,9%",{"intervention":3225,"totalTrials":1824,"cells":3288},{"EARLY_PHASE1":3289,"PHASE1":3291,"PHASE2":3293,"PHASE3":3295,"PHASE4":3297,"NA":3313},{"trials":3290,"activeCount":102},[],{"trials":3292,"activeCount":102},[],{"trials":3294,"activeCount":102},[],{"trials":3296,"activeCount":102},[],{"trials":3298,"activeCount":102},[3299,3309],{"nctId":3300,"briefTitle":3301,"status":248,"phases":3302,"primaryCompletion":3303,"completion":3303,"start":3304,"enrollment":3305,"conditions":3306,"interventions":3307},"NCT03086759","Intra-Articular Platelet Rich Plasm Use in Osteoarthritis of Knee.",[93],"2018-06-02","2017-01-02",99,[26],[3308],"Triamcinolone Hexacetonide",{"nctId":3216,"briefTitle":3217,"status":221,"phases":3310,"primaryCompletion":3219,"completion":2930,"start":3220,"enrollment":3221,"conditions":3311,"interventions":3312},[93],[26],[3224,3225,256],{"trials":3314,"activeCount":102},[3315],{"nctId":3316,"briefTitle":3317,"status":221,"phases":3318,"primaryCompletion":3319,"completion":2023,"start":3320,"enrollment":210,"conditions":3321,"interventions":3322},"NCT01851278","Effectiveness Intraarticular Corticosteroid",[94],"2013-10","2013-04",[21],[3225,3225],{"intervention":3324,"totalTrials":98,"cells":3325},"morphine",{"EARLY_PHASE1":3326,"PHASE1":3328,"PHASE2":3330,"PHASE3":3332,"PHASE4":3334,"NA":3336},{"trials":3327,"activeCount":102},[],{"trials":3329,"activeCount":102},[],{"trials":3331,"activeCount":102},[],{"trials":3333,"activeCount":102},[],{"trials":3335,"activeCount":102},[],{"trials":3337,"activeCount":102},[3338,3346],{"nctId":3339,"briefTitle":3340,"status":248,"phases":3341,"primaryCompletion":3342,"completion":3343,"start":2796,"enrollment":349,"conditions":3344,"interventions":3345},"NCT00636415","Intra-Articular Morphine Versus Bupivacaine on Knee Motion in Patients With Osteoarthritis",[94],"2005-07","2006-12",[635],[3324],{"nctId":3347,"briefTitle":3348,"status":221,"phases":3349,"primaryCompletion":3350,"completion":3351,"start":3352,"enrollment":149,"conditions":3353,"interventions":3355},"NCT03324815","Methadone Associated With Morphine for Cancer Pain",[94],"2018-07-30","2018-08-30","2017-03-02",[3354],"Cancer",[3356,3357],"Morphine","Methadone",{"intervention":3359,"totalTrials":98,"cells":3360},"antibiotic\u002Fsteroid combination",{"EARLY_PHASE1":3361,"PHASE1":3363,"PHASE2":3365,"PHASE3":3367,"PHASE4":3369,"NA":3371},{"trials":3362,"activeCount":102},[],{"trials":3364,"activeCount":102},[],{"trials":3366,"activeCount":102},[],{"trials":3368,"activeCount":102},[],{"trials":3370,"activeCount":102},[],{"trials":3372,"activeCount":102},[3373,3383],{"nctId":3374,"briefTitle":3375,"status":248,"phases":3376,"primaryCompletion":3343,"completion":3377,"start":1995,"enrollment":3378,"conditions":3379,"interventions":3381},"NCT00331084","Efficacy\u002FSafety of Antibiotic Steroid Combination in Prevention of Postoperative Inflammation in Cataract Surgery",[94],"2007-03",132,[3380],"Inflammation Following Cataract Surgery",[3359,3382],"moxifloxacin \u002F dexamethasone",{"nctId":3384,"briefTitle":3385,"status":248,"phases":3386,"primaryCompletion":3387,"completion":3343,"start":1995,"enrollment":3388,"conditions":3389,"interventions":3391},"NCT00330824","Efficacy\u002FSafety of Antibiotic Steroid Combination in Prevention of Post Operative Inflammation in LASIK Surgery",[94],"2006-09",64,[3390],"Post Lasik Surgery Inflammation",[3359,3392],"moxifloxacin\u002Fdexamethasone",{"intervention":3394,"totalTrials":98,"cells":3395},"Simvastatin",{"EARLY_PHASE1":3396,"PHASE1":3398,"PHASE2":3400,"PHASE3":3402,"PHASE4":3404,"NA":3414},{"trials":3397,"activeCount":102},[],{"trials":3399,"activeCount":102},[],{"trials":3401,"activeCount":102},[],{"trials":3403,"activeCount":102},[],{"trials":3405,"activeCount":102},[3406],{"nctId":3407,"briefTitle":3408,"status":221,"phases":3409,"completion":2475,"start":2475,"enrollment":349,"conditions":3410,"interventions":3413},"NCT00291863","Simvastatin Effect on End Stage Renal Failure Patients Treated by Peritoneal Dialysis",[93],[3411,3412],"Renal Failure, End Stage","Peritoneal Dialysis",[3394],{"trials":3415,"activeCount":102},[3416],{"nctId":3417,"briefTitle":3418,"status":248,"phases":3419,"primaryCompletion":3420,"completion":1195,"start":2795,"enrollment":686,"conditions":3421,"interventions":3425},"NCT01103648","Effect of Simvastatin and Ezetimibe on Lipid and Inflammation",[94],"2006-05",[3422,3423,29,3424],"Prediabetes","Hypercholesterolemia","Cardiovascular Risk",[3394,3426,3427],"Ezetimibe","Combination Simvastatin plus Ezetimibe",{"intervention":3224,"totalTrials":98,"cells":3429},{"EARLY_PHASE1":3430,"PHASE1":3432,"PHASE2":3434,"PHASE3":3436,"PHASE4":3438,"NA":3444},{"trials":3431,"activeCount":102},[],{"trials":3433,"activeCount":102},[],{"trials":3435,"activeCount":102},[],{"trials":3437,"activeCount":102},[],{"trials":3439,"activeCount":102},[3440],{"nctId":3216,"briefTitle":3217,"status":221,"phases":3441,"primaryCompletion":3219,"completion":2930,"start":3220,"enrollment":3221,"conditions":3442,"interventions":3443},[93],[26],[3224,3225,256],{"trials":3445,"activeCount":102},[3446],{"nctId":3447,"briefTitle":3448,"status":248,"phases":3449,"primaryCompletion":1539,"completion":1539,"start":250,"enrollment":149,"conditions":3450,"interventions":3452},"NCT01691651","Botulinum Toxin A for the Treatment of Keratoconus",[94],[3451],"Keratoconus",[3224],{"intervention":3454,"totalTrials":120,"cells":3455},"QUALI",{"EARLY_PHASE1":3456,"PHASE1":3458,"PHASE2":3460,"PHASE3":3462,"PHASE4":3464,"NA":3466},{"trials":3457,"activeCount":102},[],{"trials":3459,"activeCount":102},[],{"trials":3461,"activeCount":102},[],{"trials":3463,"activeCount":102},[],{"trials":3465,"activeCount":102},[],{"trials":3467,"activeCount":102},[3468],{"nctId":3469,"briefTitle":3470,"status":3471,"phases":3472,"conditions":3473,"interventions":3475},"NCT05753943","CLINICAL TRIAL PHASE II, MULTICENTRIC, NATIONAL, DOUBLE-BLIND, PARALLEL, RANDOMIZED, AND PLACEBO-CONTROLLED FOR EVALUATION OF THE IMPROVEMENT OF SLEEP QUALITY IN PARTICIPANTS OF RESEARCH WITH INSOMNIA DISORDER","NO_LONGER_AVAILABLE",[],[3474],"Sleep Initiation and Maintenance Disorders",[3454],{"intervention":3477,"totalTrials":120,"cells":3478},"TL+D antiretroviral",{"EARLY_PHASE1":3479,"PHASE1":3481,"PHASE2":3483,"PHASE3":3485,"PHASE4":3487,"NA":3489},{"trials":3480,"activeCount":102},[],{"trials":3482,"activeCount":102},[],{"trials":3484,"activeCount":102},[],{"trials":3486,"activeCount":102},[],{"trials":3488,"activeCount":102},[],{"trials":3490,"activeCount":102},[3491],{"nctId":3492,"briefTitle":3493,"status":248,"phases":3494,"primaryCompletion":3495,"completion":3495,"start":3496,"enrollment":3497,"conditions":3498,"interventions":3500},"NCT07618507","Resistance Profile to Antiretroviral Medications in Individuals Living With HIV Who Failed a First-Line Regimen With Tenofovir \u002F Lamivudina and Dolutegravir in Brasil",[94],"2024-03-08","2022-04-13",777,[352,3499],"HIV -1 Infection",[3477],{"intervention":3502,"totalTrials":120,"cells":3503},"Suprascapular nerve block with bipuvacaine",{"EARLY_PHASE1":3504,"PHASE1":3506,"PHASE2":3508,"PHASE3":3510,"PHASE4":3512,"NA":3514},{"trials":3505,"activeCount":102},[],{"trials":3507,"activeCount":102},[],{"trials":3509,"activeCount":102},[],{"trials":3511,"activeCount":102},[],{"trials":3513,"activeCount":102},[],{"trials":3515,"activeCount":102},[3516],{"nctId":3517,"briefTitle":3518,"status":248,"phases":3519,"primaryCompletion":3520,"completion":3521,"start":3522,"enrollment":149,"conditions":3523,"interventions":3529},"NCT05778422","Bupivacaine or Radiofrequency for Shoulder Pain",[94],"2022-01-01","2023-01-01","2021-01-01",[3524,3525,3526,3527,3528],"Shoulder Pain","Rotator Cuff Impingement Syndrome","Impingement Syndrome","Adhesive Capsulitis","Rotator Cuff Injuries",[3502],{"intervention":3531,"totalTrials":120,"cells":3532},"predinose",{"EARLY_PHASE1":3533,"PHASE1":3535,"PHASE2":3537,"PHASE3":3539,"PHASE4":3541,"NA":3543},{"trials":3534,"activeCount":102},[],{"trials":3536,"activeCount":102},[],{"trials":3538,"activeCount":102},[],{"trials":3540,"activeCount":102},[],{"trials":3542,"activeCount":102},[],{"trials":3544,"activeCount":102},[3545],{"nctId":3546,"briefTitle":3547,"status":221,"phases":3548,"primaryCompletion":3549,"completion":3270,"start":2593,"enrollment":210,"conditions":3550,"interventions":3552},"NCT01456377","The Effectiveness of Oral Corticosteroids in the Treatment of Lumbar Stenosis",[94],"2012-02",[3551],"Spinal Stenosis of Lumbar Region",[3531],{"intervention":3554,"totalTrials":120,"cells":3555},"Mitomycin",{"EARLY_PHASE1":3556,"PHASE1":3558,"PHASE2":3560,"PHASE3":3562,"PHASE4":3564,"NA":3566},{"trials":3557,"activeCount":102},[],{"trials":3559,"activeCount":102},[],{"trials":3561,"activeCount":102},[],{"trials":3563,"activeCount":102},[],{"trials":3565,"activeCount":102},[],{"trials":3567,"activeCount":102},[3568],{"nctId":3569,"briefTitle":3570,"status":248,"phases":3571,"primaryCompletion":1043,"completion":3572,"start":1836,"enrollment":3573,"conditions":3574,"interventions":3576},"NCT00654888","Automated Lamellar Keratectomy in Symptomatic Patients With Bullous Keratopathy",[94],"2008-02",28,[3575],"Corneal Disease",[3554],{"intervention":3578,"totalTrials":120,"cells":3579},"Tramadol 2mg\u002Fkg",{"EARLY_PHASE1":3580,"PHASE1":3582,"PHASE2":3584,"PHASE3":3586,"PHASE4":3588,"NA":3590},{"trials":3581,"activeCount":102},[],{"trials":3583,"activeCount":102},[],{"trials":3585,"activeCount":102},[],{"trials":3587,"activeCount":102},[],{"trials":3589,"activeCount":102},[],{"trials":3591,"activeCount":102},[3592],{"nctId":3593,"briefTitle":3594,"status":1085,"phases":3595,"primaryCompletion":3065,"completion":1539,"start":685,"enrollment":102,"conditions":3596,"interventions":3598},"NCT01636700","Tramadol Infiltration for Tonsillectomy",[94],[3597],"Postoperative Pain",[3578,3599],"Saline solution",{"intervention":3599,"totalTrials":120,"cells":3601},{"EARLY_PHASE1":3602,"PHASE1":3604,"PHASE2":3606,"PHASE3":3608,"PHASE4":3610,"NA":3612},{"trials":3603,"activeCount":102},[],{"trials":3605,"activeCount":102},[],{"trials":3607,"activeCount":102},[],{"trials":3609,"activeCount":102},[],{"trials":3611,"activeCount":102},[],{"trials":3613,"activeCount":102},[3614],{"nctId":3593,"briefTitle":3594,"status":1085,"phases":3615,"primaryCompletion":3065,"completion":1539,"start":685,"enrollment":102,"conditions":3616,"interventions":3617},[94],[3597],[3578,3599],{"intervention":3619,"totalTrials":120,"cells":3620},"Magnesiun",{"EARLY_PHASE1":3621,"PHASE1":3623,"PHASE2":3625,"PHASE3":3627,"PHASE4":3629,"NA":3631},{"trials":3622,"activeCount":102},[],{"trials":3624,"activeCount":102},[],{"trials":3626,"activeCount":102},[],{"trials":3628,"activeCount":102},[],{"trials":3630,"activeCount":102},[],{"trials":3632,"activeCount":102},[3633],{"nctId":3634,"briefTitle":3635,"status":248,"phases":3636,"primaryCompletion":1088,"completion":1088,"start":2356,"enrollment":149,"conditions":3637,"interventions":3639},"NCT01541111","Magnesium Associated With Morphine for Cancer Pain Relief",[94],[3638],"Cancer-related Problem\u002FCondition",[3619],{"intervention":3641,"totalTrials":120,"cells":3642},"Anastrozole",{"EARLY_PHASE1":3643,"PHASE1":3645,"PHASE2":3647,"PHASE3":3649,"PHASE4":3651,"NA":3653},{"trials":3644,"activeCount":102},[],{"trials":3646,"activeCount":102},[],{"trials":3648,"activeCount":102},[],{"trials":3650,"activeCount":102},[],{"trials":3652,"activeCount":102},[],{"trials":3654,"activeCount":102},[3655],{"nctId":3656,"briefTitle":3657,"status":248,"phases":3658,"primaryCompletion":2199,"completion":1309,"start":3659,"enrollment":3660,"conditions":3661,"interventions":3662},"NCT01016665","Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy",[94],"2005-04",71,[525],[3641],{"intervention":3664,"totalTrials":120,"cells":3665},"Travoprost",{"EARLY_PHASE1":3666,"PHASE1":3668,"PHASE2":3670,"PHASE3":3672,"PHASE4":3674,"NA":3676},{"trials":3667,"activeCount":102},[],{"trials":3669,"activeCount":102},[],{"trials":3671,"activeCount":102},[],{"trials":3673,"activeCount":102},[],{"trials":3675,"activeCount":102},[],{"trials":3677,"activeCount":102},[3678],{"nctId":3679,"briefTitle":3680,"status":1085,"phases":3681,"completion":1193,"start":3023,"enrollment":149,"conditions":3682,"interventions":3684},"NCT00441181","Effects of Travoprost on Neovascular Glaucoma",[94],[3683],"Neovascular Glaucoma",[3664],{"intervention":3686,"totalTrials":120,"cells":3687},"Intravitreal Antibiotic",{"EARLY_PHASE1":3688,"PHASE1":3690,"PHASE2":3692,"PHASE3":3694,"PHASE4":3696,"NA":3698},{"trials":3689,"activeCount":102},[],{"trials":3691,"activeCount":102},[],{"trials":3693,"activeCount":102},[],{"trials":3695,"activeCount":102},[],{"trials":3697,"activeCount":102},[],{"trials":3699,"activeCount":102},[3700],{"nctId":3701,"briefTitle":3702,"status":248,"phases":3703,"primaryCompletion":3704,"completion":3705,"start":3279,"enrollment":1360,"conditions":3706,"interventions":3707},"NCT04192994","Evaluation do Early Pars Plana Vitrectomy in Acute Endophthalmitis",[94],"2020-01-01","2023-12-01",[1387],[3686],{"intervention":3709,"totalTrials":120,"cells":3710},"Vaccination against hepatitis A",{"EARLY_PHASE1":3711,"PHASE1":3713,"PHASE2":3715,"PHASE3":3717,"PHASE4":3719,"NA":3721},{"trials":3712,"activeCount":102},[],{"trials":3714,"activeCount":102},[],{"trials":3716,"activeCount":102},[],{"trials":3718,"activeCount":102},[],{"trials":3720,"activeCount":102},[],{"trials":3722,"activeCount":102},[3723],{"nctId":3724,"briefTitle":3725,"status":248,"phases":3726,"primaryCompletion":1538,"completion":2930,"start":565,"enrollment":3001,"conditions":3727,"interventions":3729},"NCT01528280","Humoral and Cellular Response in Shift Workers",[94],[3728],"Other Condition That May be a Focus of Clinical Attention",[3709],{"intervention":3731,"totalTrials":120,"cells":3732},"Anterior Juxtascleral Depot of Anecortave Acetate",{"EARLY_PHASE1":3733,"PHASE1":3735,"PHASE2":3737,"PHASE3":3739,"PHASE4":3741,"NA":3743},{"trials":3734,"activeCount":102},[],{"trials":3736,"activeCount":102},[],{"trials":3738,"activeCount":102},[],{"trials":3740,"activeCount":102},[],{"trials":3742,"activeCount":102},[],{"trials":3744,"activeCount":102},[3745],{"nctId":3746,"briefTitle":3747,"status":221,"phases":3748,"start":737,"enrollment":349,"conditions":3749,"interventions":3751},"NCT00533962","IOP Reduction After Anecortave Acetate Injection in Glaucoma Patients",[94],[151,3750],"Intraocular Pressure",[3731],{"intervention":3753,"totalTrials":120,"cells":3754},"Mitomycin C",{"EARLY_PHASE1":3755,"PHASE1":3757,"PHASE2":3759,"PHASE3":3761,"PHASE4":3763,"NA":3765},{"trials":3756,"activeCount":102},[],{"trials":3758,"activeCount":102},[],{"trials":3760,"activeCount":102},[],{"trials":3762,"activeCount":102},[],{"trials":3764,"activeCount":102},[],{"trials":3766,"activeCount":102},[3767],{"nctId":3768,"briefTitle":3769,"status":221,"phases":3770,"primaryCompletion":1193,"completion":2584,"start":3165,"enrollment":22,"conditions":3771,"interventions":3776},"NCT00551824","Evaluation of Topical Mitomycin C as Adjuvant Drug to Esophageal Dilation in Children",[94],[3772,3773,3774,3775],"Esophageal Stricture","Caustic Esophageal Stricture","Peptic Esophageal Stricture","Post-Surgical Esophageal Stricture",[3753],{"intervention":3778,"totalTrials":120,"cells":3779},"Combined Oral Contraceptive",{"EARLY_PHASE1":3780,"PHASE1":3782,"PHASE2":3784,"PHASE3":3786,"PHASE4":3788,"NA":3790},{"trials":3781,"activeCount":102},[],{"trials":3783,"activeCount":102},[],{"trials":3785,"activeCount":102},[],{"trials":3787,"activeCount":102},[],{"trials":3789,"activeCount":102},[],{"trials":3791,"activeCount":102},[3792],{"nctId":3793,"briefTitle":3794,"status":248,"phases":3795,"primaryCompletion":3796,"completion":3796,"start":3797,"enrollment":3798,"conditions":3799,"interventions":3803},"NCT03383185","Metabolic Profile of Users of Hormonal and Non-hormonal Contraceptives",[],"2015-01-01","2010-01-01",489,[3800,3801,3802],"Contraceptive Usage","Metabolic Syndrome","Body Weight Changes",[3778,3804,3805],"Progestin-only pills","Depot-Medroxyprogestereone Acetate",{"intervention":3804,"totalTrials":120,"cells":3807},{"EARLY_PHASE1":3808,"PHASE1":3810,"PHASE2":3812,"PHASE3":3814,"PHASE4":3816,"NA":3818},{"trials":3809,"activeCount":102},[],{"trials":3811,"activeCount":102},[],{"trials":3813,"activeCount":102},[],{"trials":3815,"activeCount":102},[],{"trials":3817,"activeCount":102},[],{"trials":3819,"activeCount":102},[3820],{"nctId":3793,"briefTitle":3794,"status":248,"phases":3821,"primaryCompletion":3796,"completion":3796,"start":3797,"enrollment":3798,"conditions":3822,"interventions":3823},[],[3800,3801,3802],[3778,3804,3805],{"intervention":3805,"totalTrials":120,"cells":3825},{"EARLY_PHASE1":3826,"PHASE1":3828,"PHASE2":3830,"PHASE3":3832,"PHASE4":3834,"NA":3836},{"trials":3827,"activeCount":102},[],{"trials":3829,"activeCount":102},[],{"trials":3831,"activeCount":102},[],{"trials":3833,"activeCount":102},[],{"trials":3835,"activeCount":102},[],{"trials":3837,"activeCount":102},[3838],{"nctId":3793,"briefTitle":3794,"status":248,"phases":3839,"primaryCompletion":3796,"completion":3796,"start":3797,"enrollment":3798,"conditions":3840,"interventions":3841},[],[3800,3801,3802],[3778,3804,3805],{"intervention":3264,"totalTrials":120,"cells":3843},{"EARLY_PHASE1":3844,"PHASE1":3846,"PHASE2":3848,"PHASE3":3850,"PHASE4":3852,"NA":3854},{"trials":3845,"activeCount":102},[],{"trials":3847,"activeCount":102},[],{"trials":3849,"activeCount":102},[],{"trials":3851,"activeCount":102},[],{"trials":3853,"activeCount":102},[],{"trials":3855,"activeCount":102},[3856],{"nctId":3257,"briefTitle":3258,"status":248,"phases":3857,"primaryCompletion":3260,"completion":3260,"start":565,"enrollment":149,"conditions":3858,"interventions":3859},[94],[3262],[3242,3264],{"intervention":3382,"totalTrials":120,"cells":3861},{"EARLY_PHASE1":3862,"PHASE1":3864,"PHASE2":3866,"PHASE3":3868,"PHASE4":3870,"NA":3872},{"trials":3863,"activeCount":102},[],{"trials":3865,"activeCount":102},[],{"trials":3867,"activeCount":102},[],{"trials":3869,"activeCount":102},[],{"trials":3871,"activeCount":102},[],{"trials":3873,"activeCount":102},[3874],{"nctId":3374,"briefTitle":3375,"status":248,"phases":3875,"primaryCompletion":3343,"completion":3377,"start":1995,"enrollment":3378,"conditions":3876,"interventions":3877},[94],[3380],[3359,3382],{"intervention":3879,"totalTrials":120,"cells":3880},"Metformin",{"EARLY_PHASE1":3881,"PHASE1":3883,"PHASE2":3885,"PHASE3":3887,"PHASE4":3889,"NA":3891},{"trials":3882,"activeCount":102},[],{"trials":3884,"activeCount":102},[],{"trials":3886,"activeCount":102},[],{"trials":3888,"activeCount":102},[],{"trials":3890,"activeCount":102},[],{"trials":3892,"activeCount":102},[3893],{"nctId":3894,"briefTitle":3895,"status":221,"phases":3896,"primaryCompletion":3319,"completion":1927,"start":2593,"enrollment":115,"conditions":3897,"interventions":3899},"NCT00988078","Effects of Metformin and Oral Hormonal Contraceptive in Adolescents With Polycystic Ovary Syndrome",[94],[3898],"Polycystic Ovary Syndrome",[3879],{"intervention":3392,"totalTrials":120,"cells":3901},{"EARLY_PHASE1":3902,"PHASE1":3904,"PHASE2":3906,"PHASE3":3908,"PHASE4":3910,"NA":3912},{"trials":3903,"activeCount":102},[],{"trials":3905,"activeCount":102},[],{"trials":3907,"activeCount":102},[],{"trials":3909,"activeCount":102},[],{"trials":3911,"activeCount":102},[],{"trials":3913,"activeCount":102},[3914],{"nctId":3384,"briefTitle":3385,"status":248,"phases":3915,"primaryCompletion":3387,"completion":3343,"start":1995,"enrollment":3388,"conditions":3916,"interventions":3917},[94],[3390],[3359,3392],{"intervention":3426,"totalTrials":120,"cells":3919},{"EARLY_PHASE1":3920,"PHASE1":3922,"PHASE2":3924,"PHASE3":3926,"PHASE4":3928,"NA":3930},{"trials":3921,"activeCount":102},[],{"trials":3923,"activeCount":102},[],{"trials":3925,"activeCount":102},[],{"trials":3927,"activeCount":102},[],{"trials":3929,"activeCount":102},[],{"trials":3931,"activeCount":102},[3932],{"nctId":3417,"briefTitle":3418,"status":248,"phases":3933,"primaryCompletion":3420,"completion":1195,"start":2795,"enrollment":686,"conditions":3934,"interventions":3935},[94],[3422,3423,29,3424],[3394,3426,3427],{"intervention":3427,"totalTrials":120,"cells":3937},{"EARLY_PHASE1":3938,"PHASE1":3940,"PHASE2":3942,"PHASE3":3944,"PHASE4":3946,"NA":3948},{"trials":3939,"activeCount":102},[],{"trials":3941,"activeCount":102},[],{"trials":3943,"activeCount":102},[],{"trials":3945,"activeCount":102},[],{"trials":3947,"activeCount":102},[],{"trials":3949,"activeCount":102},[3950],{"nctId":3417,"briefTitle":3418,"status":248,"phases":3951,"primaryCompletion":3420,"completion":1195,"start":2795,"enrollment":686,"conditions":3952,"interventions":3953},[94],[3422,3423,29,3424],[3394,3426,3427],{"intervention":3237,"totalTrials":120,"cells":3955},{"EARLY_PHASE1":3956,"PHASE1":3958,"PHASE2":3960,"PHASE3":3962,"PHASE4":3964,"NA":3966},{"trials":3957,"activeCount":102},[],{"trials":3959,"activeCount":102},[],{"trials":3961,"activeCount":102},[],{"trials":3963,"activeCount":102},[],{"trials":3965,"activeCount":102},[],{"trials":3967,"activeCount":102},[3968],{"nctId":3229,"briefTitle":3230,"status":248,"phases":3969,"primaryCompletion":668,"completion":666,"start":3232,"enrollment":3233,"conditions":3970,"interventions":3971},[94],[3235],[3237,3238,3239,256,3240,3239],{"intervention":3238,"totalTrials":120,"cells":3973},{"EARLY_PHASE1":3974,"PHASE1":3976,"PHASE2":3978,"PHASE3":3980,"PHASE4":3982,"NA":3984},{"trials":3975,"activeCount":102},[],{"trials":3977,"activeCount":102},[],{"trials":3979,"activeCount":102},[],{"trials":3981,"activeCount":102},[],{"trials":3983,"activeCount":102},[],{"trials":3985,"activeCount":102},[3986],{"nctId":3229,"briefTitle":3230,"status":248,"phases":3987,"primaryCompletion":668,"completion":666,"start":3232,"enrollment":3233,"conditions":3988,"interventions":3989},[94],[3235],[3237,3238,3239,256,3240,3239],{"intervention":3239,"totalTrials":120,"cells":3991},{"EARLY_PHASE1":3992,"PHASE1":3994,"PHASE2":3996,"PHASE3":3998,"PHASE4":4000,"NA":4002},{"trials":3993,"activeCount":102},[],{"trials":3995,"activeCount":102},[],{"trials":3997,"activeCount":102},[],{"trials":3999,"activeCount":102},[],{"trials":4001,"activeCount":102},[],{"trials":4003,"activeCount":102},[4004],{"nctId":3229,"briefTitle":3230,"status":248,"phases":4005,"primaryCompletion":668,"completion":666,"start":3232,"enrollment":3233,"conditions":4006,"interventions":4007},[94],[3235],[3237,3238,3239,256,3240,3239],{"intervention":3240,"totalTrials":120,"cells":4009},{"EARLY_PHASE1":4010,"PHASE1":4012,"PHASE2":4014,"PHASE3":4016,"PHASE4":4018,"NA":4020},{"trials":4011,"activeCount":102},[],{"trials":4013,"activeCount":102},[],{"trials":4015,"activeCount":102},[],{"trials":4017,"activeCount":102},[],{"trials":4019,"activeCount":102},[],{"trials":4021,"activeCount":102},[4022],{"nctId":3229,"briefTitle":3230,"status":248,"phases":4023,"primaryCompletion":668,"completion":666,"start":3232,"enrollment":3233,"conditions":4024,"interventions":4025},[94],[3235],[3237,3238,3239,256,3240,3239],{"intervention":4027,"totalTrials":120,"cells":4028},"Bupivacaine 4 mL",{"EARLY_PHASE1":4029,"PHASE1":4031,"PHASE2":4033,"PHASE3":4035,"PHASE4":4037,"NA":4039},{"trials":4030,"activeCount":102},[],{"trials":4032,"activeCount":102},[],{"trials":4034,"activeCount":102},[],{"trials":4036,"activeCount":102},[],{"trials":4038,"activeCount":102},[],{"trials":4040,"activeCount":102},[4041],{"nctId":4042,"briefTitle":4043,"status":221,"phases":4044,"primaryCompletion":4045,"completion":4046,"start":4047,"enrollment":149,"conditions":4048,"interventions":4051},"NCT03577860","Ventilation and Pulmonary Aeration, Electrical Impedance Tomography, Interscalene Brachial Plexus Block",[94],"2018-10-17","2018-12-17","2018-05-17",[4049,4050],"Brachial Plexus Block","Pulmonary Ventilation",[4027,4052],"Bupivacaine 15 mL",{"intervention":4052,"totalTrials":120,"cells":4054},{"EARLY_PHASE1":4055,"PHASE1":4057,"PHASE2":4059,"PHASE3":4061,"PHASE4":4063,"NA":4065},{"trials":4056,"activeCount":102},[],{"trials":4058,"activeCount":102},[],{"trials":4060,"activeCount":102},[],{"trials":4062,"activeCount":102},[],{"trials":4064,"activeCount":102},[],{"trials":4066,"activeCount":102},[4067],{"nctId":4042,"briefTitle":4043,"status":221,"phases":4068,"primaryCompletion":4045,"completion":4046,"start":4047,"enrollment":149,"conditions":4069,"interventions":4070},[94],[4049,4050],[4027,4052],{"intervention":4072,"totalTrials":120,"cells":4073},"Drug protocol",{"EARLY_PHASE1":4074,"PHASE1":4076,"PHASE2":4078,"PHASE3":4080,"PHASE4":4082,"NA":4084},{"trials":4075,"activeCount":102},[],{"trials":4077,"activeCount":102},[],{"trials":4079,"activeCount":102},[],{"trials":4081,"activeCount":102},[],{"trials":4083,"activeCount":102},[],{"trials":4085,"activeCount":102},[4086],{"nctId":4087,"briefTitle":4088,"status":248,"phases":4089,"primaryCompletion":2932,"completion":1446,"start":1712,"enrollment":2616,"conditions":4090,"interventions":4092},"NCT04752748","Power Doppler in Hand Joints of Early RA Patients",[],[4091],"Early Rheumatoid Arthritis",[4072],{"intervention":4094,"totalTrials":120,"cells":4095},"cabergoline",{"EARLY_PHASE1":4096,"PHASE1":4098,"PHASE2":4100,"PHASE3":4102,"PHASE4":4104,"NA":4106},{"trials":4097,"activeCount":102},[],{"trials":4099,"activeCount":102},[],{"trials":4101,"activeCount":102},[],{"trials":4103,"activeCount":102},[],{"trials":4105,"activeCount":102},[],{"trials":4107,"activeCount":102},[4108],{"nctId":4109,"briefTitle":4110,"status":248,"phases":4111,"primaryCompletion":736,"completion":1193,"start":3232,"enrollment":4112,"conditions":4113,"interventions":4115},"NCT01014793","Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients",[],19,[4114],"Acromegaly",[4094],{"intervention":4117,"totalTrials":120,"cells":4118},"bupivacaine and acupuncture",{"EARLY_PHASE1":4119,"PHASE1":4121,"PHASE2":4123,"PHASE3":4125,"PHASE4":4127,"NA":4129},{"trials":4120,"activeCount":102},[],{"trials":4122,"activeCount":102},[],{"trials":4124,"activeCount":102},[],{"trials":4126,"activeCount":102},[],{"trials":4128,"activeCount":102},[],{"trials":4130,"activeCount":102},[4131],{"nctId":4132,"briefTitle":4133,"status":248,"phases":4134,"primaryCompletion":3166,"completion":1041,"start":2796,"enrollment":349,"conditions":4135,"interventions":4137},"NCT00635037","Myofascial Pain:Acupuncture Versus Trigger Point Injection Combined With Dipyrone and Cyclobenzaprine",[94],[4136],"Myofascial Pain Syndromes",[4117],{"intervention":4139,"totalTrials":120,"cells":4140},"Bupivacaine 0,25%",{"EARLY_PHASE1":4141,"PHASE1":4143,"PHASE2":4145,"PHASE3":4147,"PHASE4":4149,"NA":4151},{"trials":4142,"activeCount":102},[],{"trials":4144,"activeCount":102},[],{"trials":4146,"activeCount":102},[],{"trials":4148,"activeCount":102},[],{"trials":4150,"activeCount":102},[],{"trials":4152,"activeCount":102},[4153],{"nctId":4154,"briefTitle":4155,"status":248,"phases":4156,"primaryCompletion":348,"completion":4157,"start":4158,"enrollment":349,"conditions":4159,"interventions":4162},"NCT02755532","Bupivacaine Pharmacokinetics in Ultrasound-guided Axillary Brachial Plexus Block.",[94],"2015-10","2014-01",[4160,4161],"Pharmacokinetics","Anesthetics, Local",[4139,4163],"Bupivacaine 0,5%",{"intervention":4163,"totalTrials":120,"cells":4165},{"EARLY_PHASE1":4166,"PHASE1":4168,"PHASE2":4170,"PHASE3":4172,"PHASE4":4174,"NA":4176},{"trials":4167,"activeCount":102},[],{"trials":4169,"activeCount":102},[],{"trials":4171,"activeCount":102},[],{"trials":4173,"activeCount":102},[],{"trials":4175,"activeCount":102},[],{"trials":4177,"activeCount":102},[4178],{"nctId":4154,"briefTitle":4155,"status":248,"phases":4179,"primaryCompletion":348,"completion":4157,"start":4158,"enrollment":349,"conditions":4180,"interventions":4181},[94],[4160,4161],[4139,4163],{"intervention":4183,"totalTrials":120,"cells":4184},"Opioid",{"EARLY_PHASE1":4185,"PHASE1":4187,"PHASE2":4189,"PHASE3":4191,"PHASE4":4193,"NA":4195},{"trials":4186,"activeCount":102},[],{"trials":4188,"activeCount":102},[],{"trials":4190,"activeCount":102},[],{"trials":4192,"activeCount":102},[],{"trials":4194,"activeCount":102},[],{"trials":4196,"activeCount":102},[4197],{"nctId":4198,"briefTitle":4199,"status":248,"phases":4200,"primaryCompletion":1308,"completion":4201,"start":2067,"enrollment":210,"conditions":4202,"interventions":4203},"NCT01541124","Morphine as First Drug for Cancer Pain",[94],"2011-11",[35],[4183],{"intervention":3286,"totalTrials":120,"cells":4205},{"EARLY_PHASE1":4206,"PHASE1":4208,"PHASE2":4210,"PHASE3":4212,"PHASE4":4214,"NA":4216},{"trials":4207,"activeCount":102},[],{"trials":4209,"activeCount":102},[],{"trials":4211,"activeCount":102},[],{"trials":4213,"activeCount":102},[],{"trials":4215,"activeCount":102},[],{"trials":4217,"activeCount":102},[4218],{"nctId":3275,"briefTitle":3276,"status":221,"phases":4219,"primaryCompletion":3278,"completion":3279,"start":3280,"enrollment":149,"conditions":4220,"interventions":4221},[94],[3282,3283,635,3284],[3286,3242],{"intervention":4223,"totalTrials":120,"cells":4224},"Ganciclovir",{"EARLY_PHASE1":4225,"PHASE1":4227,"PHASE2":4229,"PHASE3":4231,"PHASE4":4233,"NA":4235},{"trials":4226,"activeCount":102},[],{"trials":4228,"activeCount":102},[],{"trials":4230,"activeCount":102},[],{"trials":4232,"activeCount":102},[],{"trials":4234,"activeCount":102},[],{"trials":4236,"activeCount":102},[4237],{"nctId":4238,"briefTitle":4239,"status":248,"phases":4240,"primaryCompletion":666,"completion":1856,"start":1857,"enrollment":1196,"conditions":4241,"interventions":4244},"NCT01349452","Ganciclovir 0,15% Ophthalmic Gel in the Treatment of Adenovirus Keratoconjuntivitis",[94],[4242,4243],"Conjunctivitis, Viral","Adenoviridae Infections",[4223,4245],"Artificial tear",{"intervention":4245,"totalTrials":120,"cells":4247},{"EARLY_PHASE1":4248,"PHASE1":4250,"PHASE2":4252,"PHASE3":4254,"PHASE4":4256,"NA":4258},{"trials":4249,"activeCount":102},[],{"trials":4251,"activeCount":102},[],{"trials":4253,"activeCount":102},[],{"trials":4255,"activeCount":102},[],{"trials":4257,"activeCount":102},[],{"trials":4259,"activeCount":102},[4260],{"nctId":4238,"briefTitle":4239,"status":248,"phases":4261,"primaryCompletion":666,"completion":1856,"start":1857,"enrollment":1196,"conditions":4262,"interventions":4263},[94],[4242,4243],[4223,4245],{"intervention":3357,"totalTrials":120,"cells":4265},{"EARLY_PHASE1":4266,"PHASE1":4268,"PHASE2":4270,"PHASE3":4272,"PHASE4":4274,"NA":4276},{"trials":4267,"activeCount":102},[],{"trials":4269,"activeCount":102},[],{"trials":4271,"activeCount":102},[],{"trials":4273,"activeCount":102},[],{"trials":4275,"activeCount":102},[],{"trials":4277,"activeCount":102},[4278],{"nctId":3347,"briefTitle":3348,"status":221,"phases":4279,"primaryCompletion":3350,"completion":3351,"start":3352,"enrollment":149,"conditions":4280,"interventions":4281},[94],[3354],[3356,3357],{"intervention":4283,"totalTrials":120,"cells":4284},"Ropivacaine",{"EARLY_PHASE1":4285,"PHASE1":4287,"PHASE2":4289,"PHASE3":4291,"PHASE4":4293,"NA":4295},{"trials":4286,"activeCount":102},[],{"trials":4288,"activeCount":102},[],{"trials":4290,"activeCount":102},[],{"trials":4292,"activeCount":102},[],{"trials":4294,"activeCount":102},[],{"trials":4296,"activeCount":102},[4297],{"nctId":4298,"briefTitle":4299,"status":221,"phases":4300,"primaryCompletion":1087,"completion":1087,"start":4301,"enrollment":3271,"conditions":4302,"interventions":4306},"NCT02208245","Prospective Clinical Trial Comparing Infraclavicular Versus Axillary Approach to Brachial Plexus Block",[94],"2014-02",[4303,4304,4305],"Scaphoid Fractures","Distal Radius Fractures","Wrist Injury Arthrodesis",[4283],{"intervention":4308,"totalTrials":120,"cells":4309},"Phenol",{"EARLY_PHASE1":4310,"PHASE1":4312,"PHASE2":4314,"PHASE3":4316,"PHASE4":4318,"NA":4320},{"trials":4311,"activeCount":102},[],{"trials":4313,"activeCount":102},[],{"trials":4315,"activeCount":102},[],{"trials":4317,"activeCount":102},[],{"trials":4319,"activeCount":102},[],{"trials":4321,"activeCount":102},[4322],{"nctId":4323,"briefTitle":4324,"status":221,"phases":4325,"primaryCompletion":4326,"completion":4327,"start":4328,"enrollment":2797,"conditions":4329,"interventions":4331},"NCT03601533","Ultrasound-guided Genicular Nerve Block With Phenol for the Treatment of Chronic Pain Due to Knee Osteoarthritis",[94],"2018-10-01","2018-11-01","2018-06-05",[4330,35],"Osteoarthritis, Knee",[4308],{"intervention":4333,"totalTrials":120,"cells":4334},"Vasopressin",{"EARLY_PHASE1":4335,"PHASE1":4337,"PHASE2":4339,"PHASE3":4341,"PHASE4":4343,"NA":4345},{"trials":4336,"activeCount":102},[],{"trials":4338,"activeCount":102},[],{"trials":4340,"activeCount":102},[],{"trials":4342,"activeCount":102},[],{"trials":4344,"activeCount":102},[],{"trials":4346,"activeCount":102},[4347],{"nctId":4348,"briefTitle":4349,"status":248,"phases":4350,"primaryCompletion":3320,"start":2842,"enrollment":11,"conditions":4351,"interventions":4352},"NCT02053675","Hemodynamic Effects of Vasopressin in Early Septic Shock Stage",[94],[1243],[4333],{"intervention":4354,"totalTrials":120,"cells":4355},"gammaglobulin",{"EARLY_PHASE1":4356,"PHASE1":4358,"PHASE2":4360,"PHASE3":4362,"PHASE4":4364,"NA":4366},{"trials":4357,"activeCount":102},[],{"trials":4359,"activeCount":102},[],{"trials":4361,"activeCount":102},[],{"trials":4363,"activeCount":102},[],{"trials":4365,"activeCount":102},[],{"trials":4367,"activeCount":102},[4368],{"nctId":4369,"briefTitle":4370,"status":248,"phases":4371,"primaryCompletion":4372,"completion":4372,"start":4373,"enrollment":36,"conditions":4374,"interventions":4377},"NCT00661401","Specific IgG Antibody in Patients With Primary Antibody Deficiencies Treated With Subcutaneous Immunoglobulin",[94],"2002-11","2002-01",[4375,4376],"Common Variable Immunodeficiency","Agammaglobulinemia",[4354]]